



Cite this: *Chem. Soc. Rev.*, 2022, 51, 7281

Putting precision and elegance in enzyme immobilisation with bio-orthogonal chemistry

Xiaolin Pei, ^{†a} Zhiyuan Luo, ^{†a} Li Qiao, ^a Qinjie Xiao, ^a Pengfei Zhang, ^{*a} Anming Wang ^{*a} and Roger A. Sheldon ^{*bc}

The covalent immobilisation of enzymes generally involves the use of highly reactive crosslinkers, such as glutaraldehyde, to couple enzyme molecules to each other or to carriers through, for example, the free amino groups of lysine residues, on the enzyme surface. Unfortunately, such methods suffer from a lack of precision. Random formation of covalent linkages with reactive functional groups in the enzyme leads to disruption of the three dimensional structure and accompanying activity losses. This review focuses on recent advances in the use of bio-orthogonal chemistry in conjunction with rec-DNA to affect highly precise immobilisation of enzymes. In this way, cost-effective combination of production, purification and immobilisation of an enzyme is achieved, in a single unit operation with a high degree of precision. Various bio-orthogonal techniques for putting this precision and elegance into enzyme immobilisation are elaborated. These include, for example, fusing (grafting) peptide or protein tags to the target enzyme that enable its immobilisation in cell lysate or incorporating non-standard amino acids that enable the application of bio-orthogonal chemistry.

Received 6th May 2022

DOI: 10.1039/d1cs01004b

rsc.li/chem-soc-rev

^a College of Materials, Chemistry and Chemical Engineering, Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Key Laboratory of Organosilicon Material Technology, Hangzhou Normal University, Zhejiang Province, Hangzhou, 311121, Zhejiang, P. R. China

^b Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, PO Wits, 2050, Johannesburg, South Africa. E-mail: roger.sheldon@wits.ac.za

^c Department of Biotechnology, Section BOC, Delft University of Technology, van der Maasweg 9, 2629 HZ Delft, The Netherlands

[†] Zhiyuan Luo and Xiaolin Pei contributed equally to this work.

1. Introduction

Biocatalysis is green and sustainable¹ and of fundamental importance for the envisioned transition to a climate-neutral, bio-based circular economy^{2,3} and achieving the UN Sustainable Development Goals.⁴ Thanks to spectacular advances in molecular biology it has become a mature technology with industrial applications, e.g. in pharmaceuticals manufacture.^{5,6} Biocatalytic processes consist of two types: (i) fermentations using growing



Xiaolin Pei


China. His current research interest is focused on biosynthesis of fine chemicals and natural products, including discovery, directed evolution and rational design of enzymes for cascade biosynthesis.

Pei Xiaolin is an associate professor at the College of Materials, Chemistry and Chemical Engineering, Hangzhou Normal University, China. He obtained BSc (Biochemical Engineering) from Shaanxi University of Science & Technology, China, MSc (Biochemistry and Molecular Biology) from Jilin University under the supervision of Prof. Feng Yan, China and PhD (Biochemical Engineering) from Zhejiang University under the supervision of Prof. Yang Lirong,



Zhiyuan Luo

Zhiyuan Luo received his BSc degree in 2019 and is currently a master degree candidate in the Chemical Synthetic Biology lab under supervision of Prof. Anming Wang at the College of Materials, Chemistry and Chemical Engineering, Hangzhou Normal University, China. His research focuses on the covalent immobilization of proteins through Tag/Catcher system and artificial amino acids for biocatalytic applications.



microbial whole cells and (ii) reactions mediated by isolated enzymes. Whole cell mediated processes have the advantage that cofactors and fresh enzyme are continuously regenerated if necessary but the disadvantage that contamination by other (iso) enzymes present in the cells can lead to selectivity losses. Isolated enzymes are more expensive, owing to the added costs of isolation and purification, but don't have the contamination problem.

However, isolated enzymes are soluble in water which is an environmentally attractive solvent but it presents a problem for their efficient recovery and recycling. Consequently, isolated enzymes are generally applied on a single-use, throw-away basis which is both economically and environmentally unattractive and not conducive to a circular economy. This problem can be solved by immobilisation of the enzyme as a free-flowing solid, *i.e.* as a heterogeneous catalyst.⁷ Immobilisation also suppresses unfolding of the enzyme, resulting in increased thermal stability with the possibility of using the enzyme in continuous flow operation.⁸

2. Enzyme immobilisation

In this review we shall be concerned with the immobilisation of isolated enzymes. Enzyme immobilisation is divided into two categories: (i) those involving attachment to an insoluble support (carrier) (Fig. 1(A)), usually a natural or synthetic organic polymer or an inorganic solid such as silica or alumina and (ii) carrier-free self-immobilisation (Fig. 1(B)) by intermolecular cross-linking of enzyme molecules to form what is effectively an insoluble cross-linked polymer.

The first method can be subdivided on the basis of the nature of the bonding of the enzyme to the carrier. The simplest and least invasive is physical adsorption which generally works well in reactions in water-free organic media. The most well-known example of this technique is Novozyme 435 which consists of *C. antarctica* lipase (CaLB) immobilised on a macroporous resin.⁹ Alternatively, ionic bonding can be used by, for example, adsorbing the enzyme on an anionic or



Li Qiao

Li Qiao earned her MS degree (2018) from Hangzhou Normal University under the supervision of Prof. Pengfei Zhang and completed her PhD degree (2022) in chemistry at Zhejiang University under the supervision of Prof. Yanguang Wang and Prof. Ping Lu. Now she is a postdoctoral researcher in the Chemical Synthetic Biology lab at Hangzhou Normal University. Her current research focuses on organic photosynthesis and building photobiocatalysis systems based on biological semiconductors.



Pengfei Zhang

Pengfei Zhang was born in Anhui, China. He obtained his Bachelor's degree (1986) from Huabei Normal University, China, and completed his PhD degree (2001) at Zhejiang University under the supervision of Prof. Zhenchu Chen. Currently, he is a professor in the College of Science at Hangzhou Normal University. His current research effort focuses on developing green and efficient synthetic methodologies for coupling reaction, carbohydrate chemistry, enzymatic catalytic reaction, and chemical industry.



Anming Wang

Anming Wang obtained his PhD in biochemical engineering at Nanjing Tech University under the supervision of Prof. Shubao Shen and Prof. Pingkai Ouyang (An academican of the Chinese Academy of Engineering). Now, he is a professor in college of Materials, Chemistry and Chemical Engineering at Hangzhou Normal University. His research interests cover bio-orthogonal enzyme immobilization and synthetic biology.



Roger A. Sheldon

Roger Sheldon, widely known for developing the E factor for assessing environmental impacts of chemical processes, received the RSC Green Chemistry Award and the Biocat Lifetime Achievement Award for contributions to biocatalysis. He was elected a Fellow of the Royal Society (2015) and Honorary Fellow of the Royal Society of Chemistry (2019). He has a PhD from Leicester University (UK) and was at Shell Research Amsterdam (1969–1980),

DSM-Andeno (1980–1990), Delft University of Technology (1991–2007) and CEO of CLEA Technologies (2006–2015). He is currently Distinguished Professor of Biocatalysis Engineering at the University of the Witwatersrand (South Africa).






Fig. 1 Random covalent enzyme immobilisation in traditional methods: (A) carrier immobilisation model (i), glutaraldehyde-mediated; (ii), epoxy-activation; (B), carrier-free immobilisation model.

cationic ion-exchange resin, depending on the overall surface charge of the enzyme. Simple adsorption and ionic binding are widely used but they both suffer from the drawback that they are susceptible to leaching of the enzyme under aqueous conditions, depending on the pH, ionic strength and temperature, especially under the harsh conditions of many industrial processes.

Another method of binding to a carrier is affinity immobilisation which makes use of polymers containing surface chelating functionalities, such as iminodiacetic acid, preloaded with metal ions – Ni^{2+} , Zn^{2+} , Fe^{2+} , Co^{2+} and Cu^{2+} – that exhibit a strong affinity for the imidazole groups in surface histidine residues of the enzyme. It has the advantage of high activity recovery through non-invasive binding.^{10,11} Moreover, recombinant proteins are usually produced containing a so-called His-tag – a string of six to nine histidine residues – attached to the N- or C-terminus – to enable purification through affinity binding. This creates the possibility of combining enzyme isolation, purification and immobilisation into a single operation.

Leaching of enzyme from the surface of immobilisates can be circumvented by forming stronger covalent bonds between *e.g.* aldehyde or epoxide functionalities on the carrier surface and free amino groups in lysine residues present on the surface of most enzymes (Fig. 1(A)). Immobilisation through covalent bonding is widely used in industry, for example, using polymethacrylates containing epoxide functionalities.¹² Covalent bonding has the advantage of physically and chemically stable binding of the enzyme to the carrier but it is not feasible to regenerate the carrier from a spent catalyst.

Methods for immobilisation of enzymes on carriers have one serious shortcoming in common: a huge dilution of activity, ranging from 90% to >99%, accompanied by proportional reductions in catalyst and volumetric productivities (space-time yields). This problem is obviated by employing carrier-free methods in which enzyme molecules are covalently linked together to form microscopic solid particles. The most widely used method for carrier-free immobilisation is as cross-linked enzyme aggregates (CLEAs). The method, first described in 2000,¹³ involves precipitation of the enzyme from an aqueous solution as physical aggregates, without disturbing its tertiary structure. This could be by addition of, for example, a saturated

solution of ammonium sulfate at optimum pH. Subsequent cross-linking by addition of a di-aldehyde (Fig. 1(B)), usually glutaraldehyde, produces insoluble aggregates with retention of their tertiary structure and activity.

CLEAs are cost-effective¹⁴ and, since precipitation is generally used to purify enzymes, they can be produced directly from fermentation broth. They are characterised by high catalyst and volumetric productivities and improved storage and operational stability to denaturation by heat, organic solvents and autolysis. They also have excellent stability towards leaching in aqueous media and can easily be recovered and recycled. They are highly porous materials and diffusional limitations are not observed with the bioconversions commonly used in organic synthesis. CLEAs have been successfully applied with many enzymes in a wide range of industrial settings.^{14,15}

The shortcomings of CLEAs are derived from their relatively fragile and small, non-uniform particles (5–50 μm and typically below 10 μm). This is a serious drawback for operation in fixed bed reactors owing to the high pressure drop over the column. It can be counteracted by blending with non-compressible particles such as controlled-pore glass but the size and fragility of CLEA particles remains an issue for large scale applications. Alternatively, addition of a cross-linker to a suspension of an enzyme in a water-in-oil emulsion produces CLEAs as uniform enzyme microspheres-spherezymes-with a particle size of 50 μm and a size distribution of $\pm 3\%$.¹⁶ However, because of the strong and rapid covalent linkage formation using di-aldehydes, random linkage is inevitable, and some non-target enzyme proteins can be immobilised in the CLEAs (Fig. 1(B)), which hinders one-step purification and immobilisation.

More recently, enzyme immobilisation has become even more important in streamlining the biocatalytic production of chemicals in bio-refineries as a result of the increasing emphasis on the development of a circular bio-based economy. In order to optimise the cost-contribution of enzymes their immobilisation has become an integral part of biocatalytic process development that facilitates the integration of production and downstream processing.¹⁷ For example, traditionally enzymes are optimised using various protein engineering techniques and when the optimum variant has been selected an immobilisation procedure is developed. However, it could well be that the optimum enzyme variant, obtained by protein engineering, does not afford the optimum immobilised biocatalyst. It makes more sense, therefore, to integrate enzyme immobilisation into the screening protocol of the protein engineering.^{18,19}

Primarily aimed at further streamlining of biocatalytic processes, a multitude of methods for the cost-effective *in vivo* immobilisation of enzymes have been developed in recent years²⁰ by combining enzyme production with *in vivo* immobilisation to afford a one-step, cost-effective production of an immobilised enzyme. This is achieved by genetic fusion of a self-assembly promoting protein to the target enzyme. For example, certain microorganisms produce inclusions of polyhydroxyalkanoates (PHAs) for energy storage and *in vivo* fusion of the central enzyme of PHA biosynthesis, polyester synthase (PhaC), to the target enzyme affords a method for



one-step production, from a renewable resource, of an enzyme immobilised on a bio-based plastic.^{21,22}

In another variation on this theme, protein engineering was employed to optimise the production of catalytic inclusion bodies (CatIBs).²³ Bacterial inclusion bodies (IBs) are usually encountered as worthless catalytically inactive material formed as an undesirable consequence of heterologous over-expression of recombinant genes. Catalytically active IB formation can be achieved by fusing short peptide tags or aggregation-inducing protein domains to the target protein, affording cost-effective, carrier-free immobilised enzymes (CatIBs) *in vivo*.²⁴ Furthermore, the activities of CatIBs are comparable with those of the corresponding soluble enzymes, which indicates a lack of diffusion limitations. A further improvement in the context of large scale applications is provided by the development of magnetically recoverable CatIBs.²⁵ For example, magnetic cross-linked inclusion bodies of the lipase CaLB exhibited 114% activity recovery, with only 15% loss of activity after recycling 10 times due to excellent stability.²⁶

Finally, in the wake of the burgeoning circular bio-based economy, waste biopolymers^{27,28} contained in agricultural, forestry, marine wastes and food waste, are becoming available in large amounts as inexpensive carriers for enzymes. Examples include lignocellulose derived biopolymers²⁹ and magnetic cellulose.³⁰ We can expect that such renewable, biodegradable polymers will find broad applications in the cost-effective and environmentally attractive immobilisation of enzymes in the future.

Regardless of which covalent approach is used, random covalent bond formation, with various amino acid residues in the target enzyme, is a problem that needs to be addressed. It can lead to loss of tertiary structure and, consequently, loss of activity. This is a long-standing question that has attracted the attention of biologists, materials scientists and chemists.³¹ What is clearly needed to address this problem is more precision in forming covalent bonds between the enzyme and a carrier or other enzyme molecules. If this can be successfully integrated with the isolation and purification of recombinant enzymes directly from cell lysate, this will lead to cost-effective, broadly applicable methodologies.

3. Enzyme immobilisation through genetic modification

Genetic modification of enzymes has been used to facilitate their immobilisation on carriers. For example, Z_{basic2} is a silica binding module (SBM) with a size of *ca.* 7 kDa and a high positive charge density resulting from exposed clusters of multiple arginine residues on one side.³² *In vivo* attachment of Z_{basic2} to target enzymes, affords chimeric enzymes in which the positive charge density directs their non-covalent attachment to a negatively charged support such as silica. Thus, *in vivo* fusion of Z_{basic2} to a D-amino acid oxidase in *E. coli* BL21 (DE3) afforded a chimera that was subsequently non-covalently attached in a defined orientation to a silica carrier.³² The

technique was also used to immobilise enzymes in the walls of microfluidic flow reactors.^{32,33}

Similarly, *in vivo* generation of fusion constructs of cellulose-binding module (CBM) with the ω -transaminase from *Bacillus megaterium* enabled immobilisation of the CBM-tagged enzyme, with *ca.* 95% activity retention, on macroporous cellulose scaffolds derived from delignified wood.³⁴

3.1 Genetic modification for affinity immobilisation

The most widely used method is genetic insertion of poly(His) tags that can bind to metal ions. This forms the basis of the EziG (EnginZyme AB Sweden) technology for immobilisation of a broad range of enzymes.^{10,11,35–38} It involves fusion of the His6-tag to target enzymes at the N or C terminus. Following the fermentation, the His-tagged recombinant enzyme is separated from cell lysate by affinity binding of the imidazole groups in His residues to surface Ni²⁺, Co²⁺ or Fe³⁺ ions coordinated to surface iminodiacetic acid functions on controlled porosity glass (CPG). The immobilised enzymes are especially suitable for use in packed bed reactors (PBRs).¹¹ In the case of purified enzymes, the maximum loading on the EziGTM carrier is 80% (Fig. 2(A)).

However, some enzymes such as P450 monooxygenases¹¹ and ω -transaminase,³⁹ exhibited reduced activities (less than 50% of the free enzymes) which may have resulted from aggregation of enzymes in the internal pores of EziGTM and hidden active sites inaccessible for substrates.

3.2 Genetic amination and modification for directed and multi-point immobilisation

Genetic amination,^{40,41} compared to chemical amination using chemical modification *in vitro*, refers to techniques for the *in vivo* introduction of surface primary amino groups by inserting Lys in the desirable region or genetic fusion of enzymes to oligomers of amino acids containing free amino groups, *e.g.* His, Lys or Arg. This produces chimeric His-, Lys- or Arg-tagged enzymes. Depending on these residues, subsequent multi-point immobilisation on cation exchange resins and/or covalent bond formation with chemically reactive groups, have also been described.^{42,43}

For example, a tag consisting of three Lys alternating with three Gly residues at the end of the β chain, far from the active site, was used to efficiently control the immobilisation of penicillin G acylase from *E. coli* by covalent attachment to a glyoxyl agarose support.⁴⁴ The substrate could freely access the well-protected active site of the enzyme and, therefore, the immobilised PGA mutant maintained its excellent catalytic properties in the synthesis of cephalosporins.

3.2.1 Affinity binding-directed covalent attachment to supports. Metal chelate containing epoxy supports were used to covalently immobilise His-tagged proteins through a two-step process of affinity binding followed by covalent bond formation with surface epoxide groups.^{45–47} For example a poly-His-tagged glutaryl acylase, an $\alpha\beta$ -heterodimeric enzyme of significant industrial interest, was immobilised on such a support.⁴⁸ The highest selectivity in specific immobilisation was achieved by using low-density chelate groups and metals with a low affinity






Fig. 2 Scheme of directed affinity immobilisation and multipoint covalent immobilisation of enzymes by genetic modification.

(e.g. Co) (Fig. 2(B)). Effective covalent bond formation with the chelated His-tagged enzymes depends on the reaction time because of the low reactivity of epoxide group. Alternatively, the commercial epoxy support is allowed to chelate with metal ions, e.g. Co and Cu, prior to incubation with a solution of the crude His-tagged enzyme.^{46,47}

3.2.2 Cysteine-directed covalent attachment to supports. Similarly, Guisan and coworkers⁴⁹ used a novel approach to promote multipoint covalent attachment of a genetically modified PGA from *E. coli*. A single cysteine residue was inserted, using site-directed mutagenesis, into the PGA at six different regions of the enzyme that were rich in Lys residues (Fig. 2(C)). This afforded variants that, following immobilisation on disulphide containing supports, exhibited excellent stability and selectivity through additional protein rigidification. Thus, multipoint covalent attachment^{49,50} through Lys residues and the cysteine thiol group derived from replacement of GlnB380 with Cys produced an immobilisate that was 30-fold more stable than the soluble preparation towards heat and organic co-solvents, and preserved 90% of its initial activity. The remarkable enhancement of stability was attributed to the increased rigidity resulting from rational multi-point covalent attachment. Nevertheless, for high volumetric productivity,⁵¹ purified enzymes are generally necessary to avoid competing attachment of non-target proteins.

The same approach was also successfully applied to the covalent immobilisation of *Geobacillus thermocatenulatus* lipase.⁴⁰ The active site is protected and the enzyme is directed to form multipoint attachments to the support.

In methods involving poly-His tag chelation in combination with covalent bond formation, the latter can, at least partially, be random. This can be avoided by using more precise bio-orthogonal chemistry, otherwise known as orthogonal bio-conjugation with nonstandard amino acids insertion.^{52–55} Bio-orthogonal chemistry is usually defined as any chemical reaction that occurs in living systems without interfering with native biochemical processes,^{56–58} that is chemical reactions *in vivo*.^{59–62} However, the definition of bio-orthogonal chemistry has been gradually expanded to include chemical reactions *in vitro* as applied in the materials science and medical science.^{63–65}

This review focuses on biomolecule-mediated covalent ligation using a variety of so-called Tag/Catcher systems, enzyme-mediated ligation, incorporation of non-standard amino acids and tyrosine-mediated oxidation ligation for bio-orthogonal immobilisation.

4. Tag-mediated bio-orthogonal covalent immobilisation of enzymes

Protein tags are peptide sequences genetically grafted onto recombinant proteins. Grafting is usually at either the C- or N-terminus or sometimes into the coding sequence, with the specific aim of separating the recombinant protein in pure, immobilised form directly from cell lysate. A wide variety of tags are applied in biomolecule-mediated covalent immobilisation of enzymes directly from cell lysate with excellent precision and activity retention.^{66–70}

4.1 Tag-mediated self-catalytic biorthogonal ligation

4.1.1 His-tag. Bio-orthogonal chemical immobilisation of an enzyme using the His-tag methodology enables the exposure of its bioactive domain to achieve optimum activity. A stable covalent bond can be formed, for example, between the imidazole group of the terminal His in the His-tag and vinyl sulfone groups on the surface of the carrier (Fig. 3).⁷¹ The imidazole group is deprotonated at neutral pH to undergo Michael-type addition.

The method offers two significant advantages compared to existing covalent linking methods: high density and specificity. This facilitates the application of recombinant proteins in biosensor and array fabrication, and drug delivery systems, in addition to biocatalysis.^{17,35,72}

4.1.2 Cysteine-tags. Bio-orthogonal thiol–ene click chemistry is suitable for the selective immobilisation of enzymes (Fig. 4(A)).^{73,74} Two types of pathways are involved in the ligation: (i) thiol–ene free-radical addition to carbon–carbon double bonds and (ii) Michael addition of thiolate anions to electron-deficient carbon–carbon double bonds. For example, overproduction of D-sorbitol dehydrogenase (D-SDH) containing a N-His6-Cys (Cys1-DSDH) or a N-His6-Cys-Cys (Cys2-DSDH) tag was achieved using






Fig. 3 Reaction mechanism of His-tag reaction with vinyl sulfone.

Escherichia coli BL21 (DE3). These cysteine-tagged enzymes were site-specifically immobilised on electrode surfaces modified with 4-vinylaniline. The bioelectrode was applied to electro-enzymatic enantioselective reduction of *D*-fructose to *D*-sorbitol.⁷³

The combination of cysteine-tagged proteins with a thiol-ene click bio-orthogonal reaction opens up perspectives for site-specific covalent immobilisation of enzymes with high activity retention. Moreover, positioning a cysteine tag at different locations in the polypeptide chain should allow a controllable orientation of the enzyme. The method also demonstrated good potential in screening of an epidermal growth factor receptor (EGFR)-tag and its inhibitor ibrutinib.⁷⁵

When this tag is combined with streptavidin affinity technology, it can enhance the current streptavidin-based solid-phase bio-assay systems. Streptavidin (Stv-C) and streptactin present intrinsic affinity toward Strep II-tag, a synthetic peptide consisting of eight amino acids (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys), and can be fused to target recombinant proteins to facilitate their isolation, purification and immobilisation on solid carriers.⁷⁶ To further optimise the affinity and immobilisation, a streptavidin mutant was constructed by fusing a six-amino acid peptide (Gly-Gly-Ser-Gly-Cys-Pro) to its C-terminus (Fig. 4(A)).⁷⁷ This single cysteine residue functions as a unique immobilisation site for bio-orthogonal conjugation using sulfhydryl chemistry.

When five tandem cysteine repeats (Cys-tag) have been fused at termini of enzyme proteins,⁷⁸ this Cys-tag can facilitate the covalent attachment of proteins to the surface of a maleimide-modified support. In high-throughput functional proteomics as little as 5 pg of the purified Cys-tagged enhanced green fluorescent protein (EGFP) was immunodetected by this enhanced chemiluminescence system. The bio-orthogonal reaction of the sulfhydryl moiety of the Cys residue with maleimide enables the immobilisation of target enzymes on maleimide-coated surfaces (Fig. 4(B)). The novel immobilised enzyme protein




Fig. 4 Immobilisation of enzymes through terminal cysteine-tags.

mutants facilitate use in a wide variety of solid-phase diagnostic tests and biomedical assays.

Cyanobenzothiazole (CBT)-cysteine condensation can also be used to create a biorthogonal linkage with cysteine-tagged enzymes.^{79,80} Thiol addition to the cyano group affords a thioimidate I, which undergoes intramolecular reaction with the terminal amino group to form the 2-aminothiazolidine II. The latter then undergoes deamination to a thiazoline. The reaction takes place under very mild conditions, and is highly selective towards terminal cysteine-containing enzymes (Fig. 4(C)).

Most noteworthy is the reversible immobilisation of enzymes using S-S bond formation *via* this tag when the Cys residue is not essential and necessary for the target enzyme.⁸¹ On the one hand, the enzyme is covalently attached on a functionalised support and presents stronger stability than that obtained using other immobilisation methods, and on the other hand, enzymes can be removed from the support using dithiothreitol (DTT) solution when the enzyme activity has reached a low to unacceptable level. With this facile chemical treatment, the support can be regenerated and reused for the immobilisation of the next fresh batch of enzyme.

4.1.3 SNAP-tag/CLIP-tag. SNAP-tag is a variant of human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hAGT) which irreversibly transfers the alkyl group from its substrate, O6-alkylguanine-DNA, to one of its cysteine residues, thereby generating a covalent thioether bond with liberation of






Fig. 5 hAGT-mediated covalent immobilisation of enzyme protein on supports functionalised using O⁶-benzylguanine (BG) derivatives.

guanine (Fig. 5).^{82–84} It is widely used for the labelling of fusion proteins *in vivo*.⁸⁵ In order to convert this to an immobilisation methodology the SNAP-tag, which is 20 kDa in size is fused to a target protein and the fusion protein allowed to react *via* demethylation with an O⁶-benzylguanine functionalised resin.⁸⁶

CLIP-tag is a mutant of hAGT that was engineered⁸⁷ for exclusivity with O-2-benzylcytosine (BC) derivatives. SNAP- and CLIP-tags have orthogonal substrate specificities. CLIP-tag is used in conjunction with other bio-orthogonal reactions, such as BC derivatives with azide or alkynyl groups, to achieve immobilisation.⁸⁷

4.1.4 Halo-tag. Halo-tag is a suicide variant of the haloalkane dehalogenase from *Rhodococcus rhodocrous* that was specifically designed to recognise terminal chloroalkane moieties displayed on a support and rapidly (within minutes) undergo covalent ester bond formation with an aspartate residue in its active site under physiological conditions (Fig. 6).⁸⁸ Hence, Halo-tag is a useful fusion partner for enabling one-step purification and gentle, site-directed immobilisation of enzymes directly from cell lysate.

For example, Halo-tag was fused to the benzaldehyde lyase from *P. fluorescens* (PfBAL) without any negative effect on soluble expression and activity of the enzyme. It was subsequently immobilised on commercially available Halo-Link™ resin (Promega). The immobilisate was successfully reused in several consecutive batches in the condensation of benzaldehyde and acetaldehyde (Fig. 6(A)).⁸⁹ Halo-tag is also used to study drug–protein interactions.⁹⁰

4.2 Tag-mediated extra-enzymatic biorthogonal ligation

4.2.1 Biotin ligase (BirA). *E. coli* biotin ligase (BirA) catalyses the ATP-dependent covalent attachment of biotin to the lysine side chain of a 15 amino acid recognition sequence known as the “Biotin Acceptor Peptide” (BAP).⁹¹ It has many applications in biotechnology, including protein labelling,^{92,93} purification,^{94,95} and covalent immobilisation.^{91,96–98}

In vivo biotinylation was used, for example, to produce biotinylated bacterial magnetic particles (BacMPs),^{99,100} Streptavidin




Fig. 6 Immobilisation procedure and mechanism of HaloTag-enzyme on HaloLink Resin and the carbonylation reactions. (A) Reprinted with permission from ref. 89. Copyright 2017, Elsevier.

was introduced onto the biotinylated BacMPs by simple mixing to provide an attractive method for site-directed immobilisation on BacMPs.⁹⁹ Fusion of BAP to the C-terminal of beta-glucosidase from *Bacillus licheniformis*, and co-expression with BirA in *Escherichia coli* afforded the biotinylated beta-glucosidase. The latter was simultaneously isolated from cell lysate and immobilised on BacMAPs based on the high affinity between streptavidin and biotin (Fig. 7).¹⁰¹ The immobilised beta-glucosidase showed excellent specific activity and thermal stability compared to the free enzyme.




Fig. 7 Site-specific protein labeling using biotin ligase (A) and protein immobilisation by the biotinylation system *in vivo* (B).






Fig. 8 SrtA-catalysed conjugation (A) of enzyme and formation of (*S*)-ketoreductase (KRED II) ring (B) for enantioselective reduction of 2-hydroxyacetophenone.

4.2.2 Sortase A (SrtA). Sortase A (SrtA) is a transpeptidase originating from Gram positive bacteria where it catalyses the attachment of proteins to the bacterial cell wall. SrtA recognises the LPXTG (where X is any amino acid except cysteine) motif in proteins¹⁰² targeted for attachment to the cell wall peptidoglycan. Proteins expressed with this C-terminal sequence can be covalently attached to the constructs with an N-terminal glycylamide motif.¹⁰³ This forms the basis of SrtA-mediated methods for enzyme immobilisation on magnetic nanoparticles¹⁰⁴ silica, graphene,¹⁰⁵ and gold surfaces.¹⁰⁶

SrtA acts as a sort of molecular “stapler” that mediates site-specific cross-linking of enzyme molecules with increased thermal stability. For example, *Staphylococcus aureus* SrtA mediated the cross-linking of (*S*)-ketoreductase (KRED II) from *C. parapsilosis* to produce a thermostable immobilised biocatalyst for efficient enantioselective reduction of ketones.¹⁰⁷ Thus, SrtA mediated conjugation of KRED II subunits, *via* coupling of a native N-terminal glycine and an added GGGGSLPETGG peptide at the C-terminus of KRED II to form mainly cross-linked dimers and trimers. The resulting cross-linked KRED catalysed the smooth reduction of 2-hydroxyacetophenone to (*S*)-1-phenyl-1,2-ethanediol, in 99.9% yield and >99.9% enantioselectivity (Fig. 8).

The scope of the method was demonstrated in efficient, highly enantioselective reductions of a series of substituted acetophenones with a further eight KREDs.¹⁰⁷

The *S. aureus* SrtA also mediated the ligation of a range of proteins to solid supports, such as polymer beads, and glass surfaces modified to display an oligoglycine motif.^{108–110} This transpeptidation methodology provides a general, robust, and gentle approach to the selective covalent immobilisation of proteins on solid supports. SrtA-mediated ligation was also used to attach the photosystem I (PSI) complex from *Synechocystis sp.* PCC 6803 to a conductive gold surface in the desired orientation for enhancing electron transfer in the conversion of light energy to electrical energy.¹¹¹

4.2.3 Lipic acid ligase (LplA). Lipic acid ligase A (LplA)¹¹² mediates the ATP-dependent attachment of carboxylic acids to an engineered 13 amino acid lipic acid receptor peptide (LAP) that can be genetically fused to a target protein of interest. This can be utilised to introduce functional groups to enable subsequent immobilisation *via* biorthogonal reactions. For example, a variant of *E. coli* LplA catalysed the covalent attachment of 10-azidodecanoic acid which provides the possibility of utilising click chemistry¹¹³ *via* inverse-electron demand Diels–Alder reactions (IEDDA) to attach the conjugate to solid surfaces (Fig. 9)^{114,115}

5. Natural amino acid-mediated bio-orthogonal covalent immobilisation of proteins

5.1 Ligation *via* isopeptide bonds in tag/catcher systems

In covalent immobilisation through intermolecular cross-linking of enzymes, *e.g.* in CLEAs, enzyme molecules form solid state structures with increased stability and facile recovery. However, building proteins into larger, post-translational assemblies in a defined and stable way is still a challenging task. A promising approach relies on so-called tag/catcher systems (Fig. 10). Tags and Catchers usually consist of peptide/protein pairs respectively, derived from the cleavage of protein




Fig. 9 Site-specific ligation by click reaction of azide groups using lipic acid ligase and subsequent chemical modification of GFP.






Fig. 10 Construction, sequence, isopeptide bond formation mechanism and application of Tag/Catcher system used in producing self-cross-linked enzyme aggregates.

domains containing intramolecular isopeptide or ester bonds that form autocatalytically under physiological conditions. Cleavage affords a mixture of the cleaved peptide (the Tag) and the remaining polypeptide (the Catcher) which are genetically fused to recombinant proteins of interest. Intermolecular isopeptide or ester bond formation can subsequently be spontaneously reconstituted in the cell lysate. Tag/Catcher systems are widely used in numerous biotechnological and medical applications.¹¹⁶ Indeed, spontaneous covalent bond formation is potentially the most convenient and cost-effective method for one-step purification and immobilisation of enzymes.¹¹⁷

5.1.1 SpyTag/SpyCatcher. Pilins and adhesins from Gram-positive bacteria sometimes form spontaneous isopeptide bonds between Lys and Asp residues, often within immunoglobulin-like domains CnaB1 or CnaB2. SpyTag and SpyCatcher are generated by cleaving the CnaB2 domain in the fibronectin-binding protein (FbaB) from *Streptococcus pyogenes* (*Spy*) into a 13 amino acid peptide (SpyTag) and the complementary 116-residue polypeptide (SpyCatcher) (Fig. 10).¹¹⁸ The two parts can also spontaneously reconstitute to form a chemically stable isopeptide bond under a range of temperatures (at least 4–37 °C), pH values (5–8), buffers (no specific anion or cation required) and even with non-ionic detergents.^{119–122}

The Spytag/Spycatcher technology constitutes a versatile platform for the development of novel biomaterials^{69,118,123–125}

including synthetic multi-enzyme complexes for use in cascade biocatalysis.^{126–128} Thus, more efficient enzymatic cascade reactions are enabled by spatially confining enzymes using the SpyTag/SpyCatcher technology. Spatial proximity results in increased rates of mass transfer through so-called substrate channeling, *e.g.* as in metabolomes.^{69,126,127,129} Thus, fusion of *Thermomyces lanuginosus* lipase (TLL) with a carboxylic acid photodecarboxylase from *Chlorella variabilis* (CvFAP) using the Spytag/Spycatcher technique was employed in a one-pot cascade conversion of triglycerides to hydrocarbon biofuels.¹³⁰

The SpyTag/SpyCatcher technique is also used to immobilise enzymes with precision on, for example, glyoxylagarose. Thus, a fusion of the SpyTag peptide with the target enzyme is conducted *in vivo* and the resulting cell lysate is allowed to react with the SpyCatcher which is attached to the glyoxylagarose support.⁶⁸ Control of macromolecular topology with genetically encoded SpyTag–SpyCatcher chemistry^{69,123,131} is also used to engineer protein hydrogels from tandem modular elastomeric and enzyme proteins that can find applications in tissue engineering, controlled drug release¹³² and immobilisation of enzymes in multi-enzyme nanodevices.^{129,133–136}

A single target enzyme molecule can be fused to both a SpyTag and a SpyCatcher and subsequently undergo cyclisation to form circular proteins, so-called SpyRings, through intramolecular formation of the original isopeptide bond, or



formation of enzyme aggregates through intermolecular coupling.⁶⁹ Circular proteins occur widely in nature, in plants animals and bacteria, and generally exhibit exceptional thermal stability and resistance to hydrolysis and proteolysis.¹³⁷ For example, a SpyRing cyclised cephalosporin C acylase (SRCCA) was obtained by fusing SpyTag and SpyCatcher to the N- and C-termini of cephalosporin C acylase (CCA). The circular SRCCA exhibited higher thermal stability and tolerance to organic solvents and denaturation in general compared with the free CCA. In addition, the high number of Lys residues in the SpyRing of SRCCA facilitated its immobilisation by multipoint, oriented attachment to, for example, glyoxyl agarose.^{68,131}

Improved variants of the SpyTag/SpyCatcher system, obtained through the application of computer-aided design and directed evolution, have also been described.^{138–140} However, limitations of the SpyTag/SpyCatcher system are that it occurs at termini of polypeptide chains^{141,142} and that it often induces the formation of active inclusion bodies in *E. coli*.¹⁴³

5.1.2 SdyTag/SdyCatcher. The SdyTag/SdyCatcher system is derived from the closely related CnaB-domain of *Streptococcus dysgalactiae*¹¹⁶ and also involves the formation of isopeptide bonds. However, in contrast with SpyTag/SpyCatcher chemistry, ligations can also occur between N- and C-termini and internal sites under certain pH conditions. Insertion of tags in the middle of the polypeptide chain provides for diversity in selecting ligation sites.^{144,145} SdyTag has a 75-fold specificity for its native SdyCatcher and SpyTag has a 320-fold specificity for SpyCatcher.¹⁴⁵

5.1.3 SnoopTag/SnoopCatcher. Re-engineering and subsequent cleavage of the adhesin, RrgA, from *Streptococcus pneumoniae* afforded the 12-amino acid peptide, SnoopTag, and its protein partner, SnoopCatcher (13 kDa).^{119,120} Spontaneous reconstitution occurs through the formation of isopeptide bonds between Lys and Asp or Asn side-chains (Fig. 10) in >99% yield and with no cross-reaction to SpyTag/SpyCatcher.¹¹⁸

The SnoopTag/SpyCatcher pair offers a robust and facile method to immobilise enzymes.¹²² In this method BslA, a small (16 kDa) protein present in bacterial biofilms which self-assembles to form a monolayer at a hydrophobic/hydrophilic interface, is functionalised with SpyTag or SnoopTag and deposited on a surface. A fusion protein of the target enzyme with the partner protein, SpyCatcher or SnoopCatcher, is allowed to spontaneously form a covalent isopeptide bond with the SpyTag or SnoopTag function immobilised on the surface.

Enzyme cyclisation using the SpyTag/SpyCatcher or SnoopTag/SnoopCatcher systems is a simple and effective method to improve the thermal stability of enzymes. For example, construction of four cyclised variants of trehalose synthase (TreS, EC 5.4.99.16) from *Thermomonospora curvata*, using various Tag/Catcher pairs¹²⁰ led to a much larger increase in thermostability than that achieved using site-directed mutagenesis. Similarly, fusion of a Catcher module to the C-terminus of luciferase and a Tag module to its N-terminus enabled a spontaneous reaction between the Catcher and Tag to afford a circular luciferase with increased thermal stability.¹²¹

Analogous strategies can be used to assemble multi-enzyme complexes or metabolons, which are natural assemblies of enzymes functioning in cascade biosynthesis *in vivo*, such as terpene biosynthesis.¹¹⁸ It was used, for example, in a cascade synthesis of amorpho-4,11-diene.¹²⁷ An interesting elaboration of the tag/catcher theme is provided by the *in vivo* one-pot construction of immobilised multi-enzyme cascades on PHA microspheres to afford a versatile toolbox for enzyme immobilisation *in vivo*. Tag/Catcher pairs, e.g. SdyTag/SdyCatcher and SnoopTag/SnoopCatcher were genetically fused to the N- and C-termini of *Ralstonia eutropha* PHA synthase (PhaC)¹⁴⁶ to enable the *in vivo* covalent immobilisation of a monomeric amylase and a dimeric organophosphate hydrolase as target enzymes (Fig. 10).^{20,145}

5.1.4 DogTag/DogCatcher. Peptide tags enable powerful general approaches for enzyme modification and covalent immobilisation. However, the majority of peptide tags are restricted to fusion *via* the N- or C- termini of target proteins. Connecting through internal sites in the polypeptide chain is more difficult because of lower flexibility and variable environments around the active sites of enzymes. However, in contrast with other Tag/Catcher systems, the DogTag/DogCatcher pair spontaneously forms isopeptide bonds with a protein loop with retention of catalytic activity.¹³⁹

The DogTag/Dog Catcher system was derived from cleavage of a *Streptococcus pneumoniae* adhesin and optimised through structure-based design and evolution, to increase the reaction rate 250-fold (Table 1). DogTag mediated loop insertion in variants of isovaleraldehyde reductase Gre2p did not result in any significant loss of activity (Fig. 10).¹³⁹

5.2 Enzyme mediated bio-orthogonal ligation for precision immobilisation

5.2.1 Microbial transglutaminase (mTGase). Microbial transglutaminase (MTG) catalyses the cross-linking of peptide tags with proteins through isopeptide bond formation¹⁴⁹ between the γ -carboxamide moiety of a glutamine residue in one partner and the free amino group of a lysine residue in the other partner (Fig. 11). MTGs are widely used in the food industry for cross-linking proteins to improve texture. Its thermal stability and robustness in water-miscible organic solvents make MTG a useful catalyst under a broad variety of conditions. For example, an effective one-pot reaction for specific covalent modification of glutamine containing peptides and proteins was obtained by combining MTG catalysed transamidation and Cu-catalysed click chemistry involving azide–alkyne cycloaddition.^{149,150} Addition of glutathione preserved enzymatic activity in the presence of copper. Alternatively, azide–alkyne cycloaddition using strained cyclooctynes to produce tetrazine moieties provides a metal-free coupling procedure.¹⁵¹

MTG reacts with a broad range of amine substrates but is particularly effective with long-chain amines. In contrast with other enzymatic conjugation methods that react exclusively at protein termini, MTG catalysed transamidation also occurs at accessible glutamine residues located at internal sites.¹⁵²



Table 1 Characteristics of various Tag/Catcher systems for forming isopeptide bond

Tag/catcher system	Protein domain and microorganism source	Mutations		Amino acids involved in isopeptide bond formation	Partner proteins content and reaction time	Second-order rate constant for binding reaction ($M^{-1} s^{-1}$)		Ref.
		Tag	Catcher			Terminal	Internal	
SpyTag/ SpyCatcher	CnaB2, <i>Streptococcus pyogenes</i>	Q97D and K108E (SpyTag003)	T91E, Q97D, N103D, and K108E (SpyCatcher003)	Lys 31 of SpyCatcher and Asp117 of SpyTag	100 nM, 2 min	$(5.5 \pm 0.6) \times 10^5$ (sfGFP)	87 ± 8 (sfGFP)	66, 147 and 148
SdyTag/ SdyCatcher	CnaB2, <i>Streptococcus dysgalactiae</i>	N	N	Lys 31 of SdyCatcher and Asp117 of SdyTag	10 μ M, 80 min	75 ± 6 (EGFP)	N	116, 144 and 146
SnoopTag/ SnoopCatcher	RrgA, <i>Streptococcus pneumoniae</i>	N	G842T, D848G	Lys742 of DogCatcher and Asn854 of DogTag	10 μ M, 15 min	N	N	118 and 145
DogTag/ DogCatcher	RrgA, <i>Streptococcus pneumoniae</i>	G842T, N847D, and D848G	N744D, N780D, K792T, and N825D D737E and N746T	Lys742 of DogCatcher and Asn854 of DogTag	5 μ M, 5 min	1000 ± 80 (sfGFP)	760 ± 20 (sfGFP)	139 and 145

Building both a lysine and a glutamine residue into a single peptide tag, designated as a PolyTag, and fusing to either an N- or C-terminus, enables the MTG catalysed formation of cross-linked aggregates of target proteins and enzymes¹⁵³ (Fig. 11(A)). This enzyme mediated transformation starts with a nucleophilic attack of the sulfhydryl group of cysteine on the γ -carboxamide of glutamine to afford an energy-rich thioester bond. Subsequent attack of the lysine amino group on the latter results in bioconjugation through the Lys–Gln bond (Fig. 11(C)). MTG-catalysed bioconjugation was used, for example, in the site-directed, covalent immobilisation of an engineered Enterokinase (EK) on amine-modified magnetic nanoparticles (Fig. 11(B)) to afford a robust and recyclable immobilisate.^{153,154}

5.2.2 Formylglycine generating enzyme (FGE). Aldehyde tags can be used to selectively label proteins, prepare antibody-drug conjugates or to immobilise enzymes and antibodies.¹⁵⁵ The aldehyde tag is generated by genetic insertion of the LCTPSR peptide sequence into the polypeptide chain of the target enzyme, e.g. at the C terminus of a *Geobacillus sp.* lipase.¹⁵⁵ The obtained variant is subsequently co-expressed with formylglycine generating enzyme (FGE) in *E. coli*. This enables the FGE

catalysed post-translational aerobic oxidation of the cysteine residue into the non-canonical formyl glycine (FGly).

In this way a genetically encoded “aldehyde tag” was introduced into the recombinant lipase. The aldehyde tag was used to attach the target enzyme to pendant primary amine functionalities on the surface of a support *via* Schiff's base formation and subsequent reduction. Overall this affords a one-step purification and site-directed covalent immobilisation of the target enzyme.¹⁵⁵ Moreover, the novel immobilised lipase was more thermally stable than a more traditional immobilised lipase (Fig. 12). The technique was also successfully applied to immobilisation of an alkaline phosphatase (AP) and methyltryptophan oxidase (MTOX).¹⁵⁶

Alternatively, an agarose support modified with an aryl substituted pyrazolone can be used in conjunction with facile Knoevenagel condensation with the aldehyde tag (Fig. 12(B)).¹⁵⁷ Immobilisation of the *S*-transaminase from *Vibrio fluvialis* (VfTA) using this method afforded an immobilisate with high activity and stability in the conversion of pyruvate and *rac*-1-phenylethylamine (PEA) to *L*-alanine and acetophenone. Moreover, it was reused in multiple cycles without any leaching.¹⁵⁷




Fig. 11 Covalent protein assembly catalysed by microbial transglutaminase depending on polyTag. (B) Reprinted with permission from ref. 154. Copyright 2019, Elsevier.






Fig. 12 Bio-orthogonal immobilisation of aldehyde-tagged enzymes (A) on pyrazolone-functionalized support (B) and linking reaction mechanism (C).

5.2.3 Enzymatic tyrosine-based bio-orthogonal ligation

5.2.3.1 Tyrosine ligase (TL). Tyrosine ligases (TL) such as tubulin tyrosine ligase (TTL) catalyse the connection reaction of a small tyrosine derivative, which is easy to synthesize, to any protein that carries a short peptide tag (the so-called Tub-tag, VDSVEGEGEEGEE) at its C-terminus.¹⁵⁸ This novel strategy for rapid chemo-selective C-terminal protein modifications on isolated proteins or cell lysates is used in biochemistry, cell biology and immobilisation (Fig. 13).^{158,159} The canonical amino acid tyrosine is not the only substrate of TTL.^{159,160} *o*-NO₂-tyrosine,¹⁶¹ *o*-F-tyrosine,¹⁶² *o*-I-tyrosine,¹⁶³ *o*-CHO-tyrosine, *o*-NH₂-tyrosine and *o*-azido-tyrosine are also substrates.¹⁶⁴ This substrate versatility of TTL enables the facile and convenient covalent modification immobilisation, and cross-linking of enzymes.

The TTL-mediated chemo-enzymatic ligation of unnatural tyrosine derivatives such as 3-azido-L-tyrosine and 3-formyl-L-tyrosine¹⁵⁸ enabled bio-orthogonal functionalisation in a total yield of up to 99% using moderate enzyme concentrations and short reaction times. Thus, TTL-catalysed incorporation of 3-azido-L- and *O*-propargyl-L-tyrosine into the respective proteins




Fig. 13 Tubulin tyrosine ligase catalytic orthogonal immobilisation of enzymes on functionalised support. Reprinted with permission from ref. 158. Copyright 2015, John Wiley and Sons.

enables *in vitro* generation of C-terminal fused proteins using Cu-catalysed click chemistry.¹⁶⁴ However, covalent ligation occurs only at the C-termini of enzymes and is, therefore not suitable for multipoint covalent attachment to carriers.

5.2.3.2 Enzymatic oxidative ligation using tyrosinase. Introduction of an *o*-nitro tyrosine residue into a protein through amber stop codon suppression,^{165,166} followed by its reduction to an amino group enables the use of aniline coupling with Na₂S₂O₄^{165,166} or NaIO₄¹⁶⁷ in phosphate buffer at pH 6.5 as a mild, selective method for protein bio-conjugation. However, chemical methods for oxidizing tyrosine and its derivatives are generally not green and sustainable¹⁶⁷ and their scope is limited by competing oxidation of other moieties present in some proteins, *e.g.* cysteines and 1,2-diols found in glycans. This limitation was overcome by using the milder oxidant, potassium ferricyanide, in the coupling reaction (Fig. 14).¹⁶⁷⁻¹⁷¹ The method can be used in antibody-drug conjugates and enzyme immobilisation.¹⁷²




Fig. 14 Bio-orthogonal conjugation of nitrotyrosine-containing protein and ferricyanide catalysed aniline coupling.



On the other hand, some copper- and iron-dependent oxidoreductases, such as peroxidases, tyrosinase and laccase¹⁷³ catalyse the mild, aerobic one-electron oxidation of tyrosine residues in proteins to achieve bio-orthogonality. For example, tyrosinase, a di-copper oxidase, catalyses the formation of *o*-quinone moieties (dopaquinone) *via* the intermediate formation of *o*-hydroxytyrosine.

This constitutes the first step in so-called melanogenesis, *i.e.* the biosynthesis of the natural pigments, melanins. Alternatively, intermolecular condensation of the *o*-quinone moiety with reactive functionalities, such as thiol and amino groups, in other residues, leads to cross-linking of the protein molecules. This is widely used in the processing of meat, whey and flour proteins to modify the texture of foods.^{174–176}

Similarly, tyrosinase catalyses aerobic oxidation of exposed tyrosine residues into *o*-quinones that subsequently react rapidly with cysteine residues on target peptides and proteins to afford a convenient synthesis of bio-conjugates. It was used, for example, to achieve a 20-fold enhancement of the cellular delivery of CRISPR-Cas9 by attaching cationic peptides.¹⁷⁷ Tyrosinase-mediated oxidative coupling of tyrosine tags on peptides and proteins has been applied (Fig. 15).^{170,178,179}

Tyrosinase from *Agaricus bisporus* (abTYR), catalysed the oxidation of tyrosine to *o*-quinone intermediates which coupled with N-terminal proline residues in high yield. This coupling strategy was successfully used for the attachment of a variety of phenols to a series of protein substrates, including self-assembled viral capsids, enzymes, and a chitin binding domain (CBD).¹⁸⁰




Fig. 15 Site-Specific bioconjugation (A) and mechanism (B) through enzymatic tyrosine–cysteine bond formation.




Fig. 16 HRP-catalysed conjugation of enzyme proteins with Y-tag at the N-termini and C-termini.

Mushroom tyrosinase catalyses the formation of reactive *o*-quinones on unstructured, tyrosine-rich sequences such as hemagglutinin (HA) tags, YPYDVPDYA.¹⁸¹ The method is used to modify the C-termini of antibodies and proteins.¹⁷⁰

5.2.3.3 Other oxidoreductases. Genetically attaching a Y-tag (GGGGY or GGYYY) peptide to the C-terminus of alkaline phosphatase (BAP)¹⁸² from *Escherichia coli* afforded a BAP construct (Fig. 16(A)). Subsequently, horseradish peroxidase (HRP) catalyses the hydrogen peroxide oxidation of exposed tyrosine residues on Y-tag to form phenoxyl radicals, resulting in the site-specific formation of highly cross-linked conjugates *via* a radical coupling reaction. When used in chemical labeling, HRP-catalysed ligation also proceeded better than other oxidative coupling between *N*-methyliminol and tyrosine residues on protein,¹⁸³ which resulted from its priority activation of *N*-methyliminol (Fig. 16(B)) in the presence of small amounts of H₂O₂.

Similarly, laccases catalyse the aerobic one-electron oxidation of tyrosine, tryptophan, and cysteine residues to form radicals which subsequently form mixtures of oligomers and




Fig. 17 Laccase-catalysed site-specific enzyme protein cross-linking reaction. (A) Reprinted with permission from ref. 186. Copyright 2018, Elsevier.



polymers.¹⁸⁴ This can be used to perform site-specific cross-linking of enzyme proteins with peptide tags.¹⁸⁵ For example, both BAP and antibody-binding proteins (pG2PAs)¹⁸⁶ contain a tyrosine residue (Y-tag) at the N- or C-termini (Fig. 17), which is oxidised by laccase to afford protein polymers. Co-polymers of BAP and pG2PA were also prepared by mixing aqueous solutions of small Y-tagged substrates.

6. Bio-orthogonal immobilisation mediated by non-standard amino acids (NSAAs)

Traditional covalent immobilisation methods often lead to loss of activity and accompanying reduced catalyst and volumetric productivities, through the random formation of covalent bonds with the enzyme.⁵¹ It is especially important, therefore, to achieve more precision in covalent bond formation to fully retain or even enhance activity. Genetic encoding of NSAAs is one way to achieve this. Random and unwanted covalent linkages are circumvented by incorporating NSAAs with reactive groups into the enzyme to enable mild and precise bio-orthogonal coupling of the enzyme to a carrier or to other molecules of the enzyme in cell lysate.

Genetic code expansion is used to insert non-standard amino acids into a single site^{52,187} or multiple sites^{54,188} of proteins. This enables the site-specific or multi-point covalent attachment of enzymes using bio-orthogonal chemistry. A variety of covalent ligation reactions, such as copper-catalysed azide-alkyne cycloadditions (CuAAC),^{189–191} strain-promoted azide-alkyne cycloadditions (SPAAC),¹⁹² and inverse-electron demand Diels-Alder reactions (IEDDA), are used depending on the nature of the inserted NSAA. The natural genetic code only allows for 20 standard amino acids in protein translation but recently developed biosynthetic approaches enable the insertion of non-standard amino acids (NSAAs). Thus far, nearly 200 distinct NSAAs were incorporated into proteins to endow them with novel physical, chemical, and biological properties.¹⁹³

6.1 Copper-catalysed azide-alkyne cycloadditions (CuAAC)

The copper-catalysed azide-alkyne coupling (CuAAC), the classic example of Click chemistry, was independently reported by Sharpless and Meldal in 2001.¹⁹⁴ It has been widely used in biology, materials science and biomedicine.^{190,195} It is a versatile reaction based on its exquisite selectivity and diversity of building blocks that can be synthesized and the fact that the triazole products are extremely stable under physiological conditions. The method is suitable for protein labelling,^{191,196} biomolecular ligation^{197–199} and enzyme immobilisation.^{200–203}

The utilisation of NSAAs has proven to be an effective method for site-specific immobilisation of proteins.²⁰³ Every protein molecule is covalently attached to a support at the same site. For example, the non-standard *p*-azido-*L*-phenylalanine (*p*-AzF) was inserted into a GFP reporter system for site-specific covalent immobilisation on solid-carriers.²⁰² Recently,




Fig. 18 Process for preparing alcohol dehydrogenase cross-linked enzymes (CLEs) from cell lysate. Reprinted with permission from ref. 190. Copyright 2021, American Chemical Society.

we incorporated another *p*-propargyloxy-*L*-phenylalanine (*p*-PaF) into a KRED, and then induced the formation of cross-linked enzymes (CLEs) by adding bis-PEG₃-azide and CuI to cell lysate in a microwave reactor.¹⁹⁰ The robust CLEs were combined with TiO₂ and Cp*Rh(bpy) to develop a biohybrid photocatalytic hydrogenation system, which was used in the enantio-selective synthesis of *R*-1-[3,5-bis(trifluoromethyl)-phenyl]ethanol, an important intermediate in the synthesis of the anticancer drug Crezotinib (Fig. 18).

The copper catalyst is usually prepared with an appropriate chelating ligand to maintain the Cu(I) oxidation state.²⁰⁴ The cycloaddition reaction between azide and alkyne is usually performed in aqueous buffer to produce a stable and inert 1,4-triazole.²⁰⁵

6.2 Strain-promoted azide-alkyne cycloadditions (SPAAC)

Cyclooctyne is the smallest stable cyclic alkyne and is distorted by 17° from the preferred linear alkyne geometry. This results in sufficient ring strain to enable metal-free [3+2] cycloaddition of azides. Hence, the reaction's name: strain-promoted azide-alkyne cycloaddition (SPAAC).²⁰⁶ Biological applications of this reaction have generally been limited by its low reaction rate but the latter can be accelerated using microwave irradiation of low power at low temperatures.²⁰⁷

Amber codon suppression was used to replace five tyrosine residues (Tyr50, 137, 243, 274, and 355) with azido phenylalanine in a recombinant lipase. The mutants were coupled to a solid support using the SPAAC reaction and the obtained AzPhe-Lip243 and AzPhe-Lip274 showed higher catalytic activity compared with the natural enzyme. This clearly demonstrates the importance of NSAA insertion for directing covalent immobilisation.²⁰² The method has broad scope in one-step






Fig. 19 Preparation, reaction mechanism and morphology of rapidly and precisely cross-linked enzymes (RP-CLEs) of aldehyde ketone reductase. Reprinted with permission from ref. 192. Copyright 2020, American Chemical Society.

enzyme purification and immobilisation of enzymes. It was used, for example, in the multiple site insertion of *p*-azido-L-Phe (*p*-AzF) in an aldehyde ketone reductase (AKR) followed by immobilisation as cross-linked enzymes (CLEs) directly from cell lysate supernatant under microwave irradiation.¹⁹² The specific activities of the AKR-CLEs were 1–2 times that of the free enzyme (Fig. 19). The method has the potential to generate a range of bio-orthogonally cross-linked enzymes, for use in industrial biocatalysis, directly from cell lysate.

López-Gallego and coworkers²⁰⁸ have developed a one-pot cell-free protein synthesis (CFPS) and immobilisation to enable on-demand fabrication of protein-based biomaterials. It involved the incorporation of azide-substituted amino acids into nascent proteins followed by selective immobilisation on a variety of solid supports using SPAAC. Here, if the insertion sites of NSAAs are rationally designed in space (Fig. 19(C)), the protein rings can be obtained²⁰⁹ and further used as protein-based biomaterials for drug delivery or directly as clinical protein.

6.3 Inverse-electron demand Diels–Alder reactions (IED-DA)

The inverse-electron-demand Diels–Alder (IEDDA) reaction involves the cycloaddition of an electron-rich dienophile with an electron-poor diene.²¹⁰ For example, cycloaddition of tetrazines with strained trans-cyclooctenes has attracted increasing attention based on its high rate, biocompatibility and scope as a site-directed bio-orthogonal technique.^{211–213} The reaction tolerates a range of buffered conditions appropriate for protein handling, requires no catalyst, and boasts tunable rate constants of up to $106 \text{ M}^{-1} \text{ s}^{-1}$, orders of magnitude faster than 3+2 cycloadditions or oxime formation.^{213–215}




Fig. 20 Bio-orthogonal immobilisation of NSAAs inserted human carbonic anhydrase II (tsCA) on TCO-functionalised surfaces. Reprinted with permission from ref. 216. Copyright 2019, American Chemical Society.

As shown in Fig. 20(A) a tetrazine containing NSAAs (Tet2.0) was genetically inserted in human carbonic anhydrase II (tsCA) to enable its IEDDA immobilisation onto trans-cyclooctene (TCO) modified surfaces.²¹⁶ By genetically encoding the Tet2.0 the precise site of incorporation, and thereby the orientation of the protein after immobilisation, can be easily controlled, as shown in Fig. 20(B). This affords a rapid, gentle and general method for bio-orthogonal immobilisation using IEDDA (Fig. 20(C)).

7. Challenges for the future

Rapid and precise covalent immobilisation of enzymes in combination with the use of continuous processing will continue to play an important role in the design of the next generation of biotechnological processes for application in a bio-based circular economy.^{217–219}

7.1 Design of an improved biological tag for covalent enzyme ligation

Genetically encoded peptide–protein coupling systems, such as the SpyTag/SpyCatcher and related two-component systems (see Section 5.1), have expanded the protein bioconjugation toolbox. More recently, three-component systems with added advantages such as SpyTag/KTag/SpyLigase,²²⁰ SnoopTagJr/DogTag/Snoop Ligase¹¹⁷ and SpyTag/BTag/Spy Stapler^{120,221} have emerged. Three-component ligation systems, such as SpyTag/KTag/SpyLigase, are expected to address the problem of formation of inclusion bodies when the 116-residue SpyCatcher is fused to target enzymes.⁶⁶ For example, in the SpyTag/KTag/SpyLigase system the original Catcher from CnaB2 is re-split into two parts, K tag and one small protein domain termed SpyLigase which catalyses the bio-orthogonal ligation of the two tags.²²⁰



Such systems possess most of the advantages of the two-component systems but require only two short peptide tags for side-chain ligation through genetic fusion. This enables the construction of large enzyme protein conjugates for covalent immobilisation directly with minimum loss of function, from expressed recombinant proteins and involving an entirely new mode of bioconjugation, that is *via* spontaneous intermolecular isopeptide bond²²² and possibly mechanical bonding.²²¹

Additional benefits to the bioconjugates, such as improved activity and stability, can also be obtained by solving the problem of the limitation of binding sites to the C- and N-termini of the target enzyme. This would result in significant improvements in covalent immobilisation *via* isopeptide formation which forms the basis for the generation of insoluble circular enzymes as elegant examples of carrier-free enzyme immobilisation that are more in line with a circular economy.

7.2 Rapid and controllable chemical linkage reaction for precise enzyme immobilisation

Traditional covalent immobilisation methods, such as using epoxide cross-linkers is time-consuming, often taking several days because of the slow linking reaction.^{223,224} Moreover, enzyme tertiary structures are often destroyed and active sites are buried. Proteolysis can also occur, resulting in substantial activity losses and decreases in volumetric productivities. All in all this results in a decrease in cost-effectiveness of the procedure.⁵¹ Thus, it is especially important from the cost-effectiveness viewpoint to achieve precise covalent cross-linking to expose fully the active sites and retain high enzyme activities, perhaps even higher than that observed *in vivo*.^{225,226}

NSAA insertion is an efficient tool for enabling covalent bond formation between the enzyme and the carrier. Thus, depending on the enzyme structure analysis, various NSAAs can be incorporated into the protein to accurately guide and control the covalent linkage to a carrier or to other enzyme molecules to form cross-linked enzyme (CLEs). This could afford a green method to generate metal-free bio-orthogonally cross-linked enzymes¹⁹² and allow their facile separation from cell lysates for industrial biocatalysis. Moreover, rapid covalent protein ligation, in several minutes¹⁶⁸ or even seconds²²⁷ *via* photo-controlled click chemistry, is ideal for protecting the enzyme from proteolysis. More than 170 NSAAs¹⁹³ have been inserted in proteins in living organisms, indicating that more and more bio-orthogonal reaction pairs can be used to cross-link enzyme proteins. This will eventually enable the construction of sequentially cross-linked multi-enzymes for *in vitro* enzymatic cascade reactions and metabolic pathways in cells thereby advancing the development of *in vitro* synthetic biology.^{228,229}

7.3 The effect of the carrier in enzyme immobilisation

This review is concerned with the use of bio-orthogonal chemistry to affect the modification of recombinant enzymes such that enzyme production and purification are combined *in vitro*. The immobilised enzyme can then be produced directly from cell lysate. The basic premise of this approach is that it will afford a cost-effective streamlining of enzyme production,

purification and immobilisation. However, this assumes that the immobilisation from cell lysate, either on a carrier or carrier-free, can be accomplished simply and cost-effectively.

The last step in this sequence is the immobilisation, which in many of the articles on the use of bio-orthogonal chemistry seems to be an underexposed part of the overall procedure. However, if this part of the procedure is not cost-effective then the procedure as a whole is not cost-effective and will not be used. It is self-evident, therefore, that methods for performing this last step in the sequence cost-effectively is a *conditio sine qua non* for the success of the overall procedure. As we noted in Section 2 developments in carriers for enzyme immobilisation tend to follow developments in chemistry as a whole, *i.e.* there is a transition from synthetic, hydrocarbon-based polymers towards bio-based polymers, preferably derived from waste biopolymers in a circular bio-based economy. In short, a major challenge for future developments in this field is to develop carriers that are of benign origin and are readily recycled in order to produce an absolute minimum of waste. This is in stark contrast with hydrocarbon-derived polymers which tend to end their life as difficult to recycle waste. Moreover, conversion of hydrocarbon polymers to functional enzyme carriers generally requires some surface modification, such as the introduction of epoxide groups that react with the enzyme. However, such 'epoxy carriers' are expensive, readily deactivated and end their life as non-recyclable waste. Hence, such carriers are gradually being phased out and already have limited commercial availability.

Hence, an important challenge for the future is the development of carriers that are produced from waste biopolymers, are readily available and recyclable and are more consistent with the general trend towards more sustainable biocatalytic processes.^{217,230,231} Carriers for enzyme immobilisation must be recyclable by design and the development of a bio-orthogonal methodology for enzyme immobilisation must involve the design of a readily available, inexpensive and eminently recyclable carrier as an integral part of the project, from the beginning, not as an afterthought.

The cost, commercial availability and recyclability of the carrier plays an important role in determining the commercial viability of the method as a whole.^{232–234} Turner and co-workers¹¹ provided guidelines for the immobilisation of enzymes for use in the pharmaceutical industry. The immobilised enzyme should have a wt loading of >10%, an activity recovery of >50%, have >20 recycles, a cost contribution of <5%, exhibit no leaching, tolerance to organic solvents, be mechanically stable in batch and in flow and good substrate mass transport.

Recently, much attention has been devoted to the use of magnetically recoverable immobilised biocatalysts, *e.g.* based on magnetic cellulose³⁰ as a technique that is used on a very large scale. Similarly, magnetic CLEAs (mCLEAs) are easily recycled using commercially available equipment.¹⁴

In the many examples discussed in Sections 4 and 5 a wide variety of carriers have been used. At the end-of-use of the enzyme, it is important that the carrier can be recycled and



re-used. In the cases of enzymes that are covalently attached, drastic conditions may be necessary to separate the carrier that may be detrimental for a polymeric carrier.²³⁵ However, if enzymes are covalently attached to the carrier by forming disulfide (S-S) bonds through non-essential thiol (SH) groups in the enzyme and reactive thiol groups on the carrier, the bound protein can be subsequently released by treatment with an excess of dithiothreitol.^{81,236} Alternatively, concentrated aqueous HCl can be used to remove the enzymes from the carrier.²³⁵ Nevertheless, after several cycles the carrier will usually be abandoned and end its life as solid waste.

Interestingly, some polymers are particularly amenable to recycling.^{237–240} With a judicious choice of monomer and polymer structures it is possible to create recyclable polymers. For example, a synthetic polymer derived from γ -butyrolactone can be easily and selectively depolymerised and the monomer used to produce pristine polymer.^{236,239} Similarly, polycarbonates derived from epoxides and carbon dioxide can be readily recycled back to the monomer and re-polymerised under mild conditions²³⁷ and recovered polydiketoenamine monomers can be re-manufactured into the same polymer formulation, without any loss of performance.²⁴⁰

7.4 Machine learning-guided rationally spatial multi-enzyme immobilisation

Machine learning has been considered as a potential strategy in the pursuit of rational immobilisation of enzymes. The CapiPy program for predicting the immobilisation properties of enzymes is based on a python algorithm.²⁴¹ The algorithm is composed of four modules, including the sequence blast and structure modelling, active site identification, surface and residue clustering, and immobilisation literature retrieval. CapiPy can conveniently help researchers to make a selection on the immobilisation approach of target protein, and has been tested using three separate random sets of 150 protein sequences with more than 70% overall success rate. In addition, enzyme-linked immunosorbent assay (ELISA) has been used to identify antibodies, antigens, proteins and glycoproteins. Polystyrene binding peptides (PSBPs) can be used to immobilise bioactive peptides, enzymes and antigens in water at room temperature. PSBP-SWM, a machine learning-based computational identifier, was developed to predict PSBPs for correct recognition in ELISA. The machine-based identification model contains four steps, including feature extraction, feature selection, model training and optimisation.²⁴²

In the last decade, metal-organic frameworks (MOFs) have proven to be a good platform for the immobilisation of enzymes. To save experimental time and cost, several machine learning algorithms (random forest and Gaussian process regression) were used to predict enzyme-MOF properties, including enzyme loading, activity retention, immobilisation yield and reusability.²⁴³ Recently, Raman hyperspectral imaging with principal component analysis has been developed to discern the spatial and chemical distribution of immobilised enzymes.²⁴⁴ Furthermore, chemical imaging has been combined with machine learning to elucidate the immobilisation

of enzymes for biocatalysis. The machine learning was based on multivariate curve resolution-alternating least squares (MCR-ALS), which was used to explain pure response profiles of the chemical constituents within a complex.²⁴⁵ Machine learning can be used to understand and improve enzyme immobilisation for biocatalytic processes, and is likely to become an active research area in the near future.

In striking contrast with the elegant orchestration of multiple biocatalytic steps in metabolic pathways in living cells, classical multi-step organic syntheses *in vitro* are performed in a step-by-step fashion involving isolation and often purification of intermediates and/or a solvent switch after each individual step. This affords low volumetric productivities combined with copious waste formation. The number and amounts of solvent used and the amounts of waste generated are substantially reduced by telescoping such multi-step syntheses into one-pot procedures that have higher productivities, involve fewer unit operations, smaller reactor volumes and shorter cycle times.²⁴⁶

One problem of creating chemocatalytic cascade processes is that the individual steps often involve vastly different conditions of temperature, pressure and solvent. In contrast, the vast majority of enzymes perform admirably in water as the solvent at ambient temperature and pressure at a defined pH. Furthermore, because of the exquisite specificity of enzymes functional group activation and protection and deprotection steps, necessary in many chemocatalytic reactions, become redundant in biocatalytic equivalents. Moreover, coupling biocatalytic steps offers the possibility of driving equilibria towards product formation by product removal.

As is also the case with individual biocatalytic reactions, immobilisation of the individual enzymes involved in a biocatalytic cascade process offers obvious processing advantages. A further advantage is that it is possible to co-immobilise enzymes that are incompatible in homogeneous solution. An excellent example of this is the co-immobilisation of a protease and a lipase in a combi-CLEA.²⁴⁷

In order to facilitate recycling, multiple enzymes can be co-immobilised on a carrier, *e.g.* for the manufacture of islatravir,²⁴⁸ or by cross-linking. Co-immobilisation offers the additional benefit of enzyme proximity that enables substrate channeling in which the intermediate produced by one enzyme is transferred to the next enzyme without intermediary mixing in the homogeneous phase, leading to reductions in diffusion times, higher overall activities and less accumulation of inhibitory intermediates.^{249,250} This phenomenon occurs widely in nature, for example in multi-enzyme cellulosomes consisting mainly of carbohydrases that catalyse the hydrolysis of cellulose and hemicellulose.²⁵¹ An interesting example of such a co-immobilisation is the His-tagged ketoreductase (KRED) and His-tagged GDH attached to functionalised magnetic beads for enantioselective reduction of prochiral ketones.²⁵²

Compartmentalisation is fundamental to the functioning and protection from cellular degradation mechanisms of multiple enzymes in metabolic pathways. Much research is devoted, therefore, to designing compartmentalised cascade processes



with isolated enzymes *in vitro* that emulate this exquisite orchestration of multi-enzyme metabolic pathways *in vivo*.²⁵³ The use of enzyme data bases such as EnzymeML and SABIO-RK²⁵⁴ in combination with machine-assisted learning²⁵⁵ and the use of microfluidics and robotics will play an important role in designing the next generation of biotechnological processes involving enzyme cascades in compartments.²⁵⁶ We expect that the design of efficient bio-orthogonal methods for precision co-immobilisation of multiple enzymes will play an indispensable role in these developments.

8. Conclusions and prospects

Enzyme immobilisation continues to be a subject of immense interest, in both industry and academia. The commercial viability of industrial biotransformations stands or falls with the cost contribution of the enzyme. Immobilisation is an enabling technology that, in addition to providing an active and stable biocatalyst, should be a relatively simple operation not requiring a highly pure enzyme preparation or an expensive support that may not be commercially available. This review is concerned with the progress of covalent immobilisation of enzymes directly from cell lysates with emphasis on the use of elegant bio-orthogonal chemistry to achieve precision in immobilisation. Bio-orthogonal chemistry has three main advantages: (i) no disruption in the structure and functioning of the enzyme, (ii) the key chemistry is integrated in the production of the recombinant enzyme and immobilisation occurs directly from cell lysate to afford a cost-efficient, green and sustainable methodology and (iii) the method is applicable to the immobilisation of enzymes either on carriers or as cross-linked enzyme aggregates.

Bio-orthogonal immobilisation through, for example, genetic encoding of NSAAs and subsequent covalent bond formation allows for control of the precise position, number and manner of the covalent bond formation. Random covalent bond formation, leading to loss of activity and function that is often observed with traditional covalent immobilisation, is avoided. We expect that further integration of protein engineering with bio-orthogonal immobilisation directly from cell lysate and supported by machine learning will put precision and elegance into enzyme immobilisation to enable cost effective biocatalysis in a sustainable circular bioeconomy.

Which method shows the most promise? It is difficult to say but based on the enormous advances made in the incorporation of NSAAs in protein sequences it seems likely that significant advances will be made in the use of NSAAs for guiding the efficient immobilisation of enzymes directly from cell lysate. One way to avoid the complications associated with finding a suitable carrier is to avoid it altogether by using carrier-free immobilised enzymes. In this context the formation of circular proteins *via* isopeptide bonds is of particular interest.

In any case, we predict that the combination of innovative bio-orthogonal chemistry with enzyme immobilisation

techniques will stimulate the further development and reduction to commercial practice of continuous-flow biocatalysis.^{8,257} This could be used, for example, to drive *in vitro* multi-enzyme cascade processes, in emulation of the exquisite orchestration of metabolic pathways *in vivo*, and provide truly sustainable biocatalytic methods for the industrial production of chemicals.^{257–261}

Author contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (22078079), the “Ten-thousand Talents Plan” of Zhejiang Province (2019R51012), the Natural Science Foundation of Zhejiang Province (LY18B060009), the “Star and light” Project for Talent Students in Hangzhou Normal University (2019) and Research Plan for Sprout Talents in University in Zhejiang Province (2020R427071).

Notes and references

- R. A. Sheldon and J. M. Woodley, *Chem. Rev.*, 2018, **118**, 801–838.
- C. Raffaele and C. Daniele, *Recycling*, 2018, **3**, 22.
- P. Intasian, K. Prakinee, A. Phintha, D. Trisrivirat, N. Weeranoppanant, T. Wongnate and P. Chaiyen, *Chem. Rev.*, 2021, **121**, 10367–10451.
- D. Firoiu, G. H. Ionescu, A. Bndoi, N. M. Florea and E. Jianu, *Sustainability*, 2019, **11**, 2156.
- P. N. Devine, R. M. Howard, R. Kumar, M. P. Thompson, M. D. Truppo and N. J. Turner, *Nat. Rev. Chem.*, 2018, **2**, 409–421.
- H. H. Sun, H. F. Zhang, E. L. Ang and H. M. Zhao, *Bioorg. Med. Chem.*, 2018, **26**, 1275–1284.
- R. A. Sheldon, A. Basso and D. Brady, *Chem. Soc. Rev.*, 2021, **50**, 5850–5862.
- P. De Santis, L.-E. Meyer and S. Kara, *React. Chem. Eng.*, 2020, **5**, 2155–2184.
- C. Ortiz, M. L. Ferreira, O. Barbosa, J. C. S. dos Santos, R. C. Rodrigues, Á. Berenguer-Murcia, L. E. Briand and R. Fernandez-Lafuente, *Catal. Sci. Technol.*, 2019, **9**, 2380–2420.
- K. E. Cassimjee, M. Kadow, Y. Wikmark, M. S. Humble, M. L. Rothstein, D. M. Rothstein and J. E. Backvall, *Chem. Commun.*, 2014, **50**, 9134–9137.



- 11 M. P. Thompson, S. R. Derrington, R. S. Heath, J. L. Porter, J. Mangas-Sanchez, P. N. Devine, M. D. Truppo and N. J. Turner, *Tetrahedron*, 2019, **75**, 327–334.
- 12 B. Chen, J. Hu, E. M. Miller, W. Xie, M. Cai and R. A. Gross, *Biomacromolecules*, 2008, **9**, 463–471.
- 13 L. Q. Cao, F. van Rantwijk and R. A. Sheldon, *Org. Lett.*, 2000, **2**, 1361–1364.
- 14 R. A. Sheldon, *Catalysts*, 2019, **9**, 261–291.
- 15 H. Yamaguchi, Y. Kiyota and M. Miyazaki, *Catalysts*, 2018, **8**, 174–190.
- 16 M. B. Mbanjwa, K. J. Land, T. Windvoel, P. M. Papala, L. Fourie, J. G. Korvink, D. Visser and D. Brady, *Process Biochem.*, 2018, **69**, 75–81.
- 17 R. A. Sheldon and D. Brady, *ACS Sustain. Chem. Eng.*, 2021, **9**, 8032–8052.
- 18 C. Bernal, K. Rodríguez and R. Martínez, *Biotechnol. Adv.*, 2018, **36**, 1470–1480.
- 19 M. Bilal and H. M. N. Iqbal, *Catal. Lett.*, 2019, **149**, 2204–2217.
- 20 G. Ölçücü, O. Klaus, K.-E. Jaeger, T. Drepper and U. Krauss, *ACS Sustain. Chem. Eng.*, 2021, **9**, 8919–8945.
- 21 F. B. H. Rehm, S. Chen and B. H. A. Rehm, *Bioengineered*, 2018, **9**, 6–11.
- 22 F. B. H. Rehm, S. Chen and B. H. A. Rehm, *Molecules*, 2016, **21**, 1370–1388.
- 23 V. D. Jaeger, R. Lamm, K. Kuesters, G. Oelcuecue, M. Oldiges, K.-E. Jaeger, J. Buechs and U. Krauss, *Appl. Microbiol. Biotechnol.*, 2020, **104**, 7313–7329.
- 24 J. M. Sanchez, H. Lopez-Laguna, N. Serna, U. Unzueta, P. D. Clop, A. Villaverde and E. Vazquez, *ACS Sustain. Chem. Eng.*, 2021, **9**, 2552–2558.
- 25 R. Koszagova, T. Krajcovic, K. Palencarova-Talafova, V. Patoprsty, A. Vikartovska, K. Pospiskova, I. Safarik and J. Nahalka, *Microb. Cell. Fact.*, 2018, **17**, 139.
- 26 Y. Han, X. Zhang and L. Zheng, *Mol. Catal.*, 2021, **504**, 111467.
- 27 M. Bilal and H. M. N. Iqbal, *Int. J. Biol. Macromol.*, 2019, **130**, 462–482.
- 28 S. Aggarwal, A. Chakravarty and S. Ikram, *Int. J. Biol. Macromol.*, 2021, **167**, 962–986.
- 29 Y. A. Rodriguez-Restrepo and C. E. Orrego, *Environ. Chem. Lett.*, 2020, **18**, 787–806.
- 30 A. Gennari, A. J. Fuhr, G. Volpato and C. F. V. de Souza, *Carbohydr. Polym.*, 2020, **246**, 116646.
- 31 R. A. Sheldon, *Adv. Synth. Catal.*, 2007, **349**, 1289–1307.
- 32 D. Valikhani, J. M. Bolivar and B. Nidetzky, *Methods Mol. Biol.*, 2020, **2100**, 243–257.
- 33 D. Valikhani, J. M. Bolivar, M. Viefhues, D. N. McIlroy, E. X. Vrouwe and B. Nidetzky, *ACS Appl. Mater. Interfaces*, 2017, **9**, 34641–34649.
- 34 A. D. Roberts, K. A. P. Payne, S. Cosgrove, V. Tilakaratna, I. Penafiel, W. Finnigan, N. J. Turner and N. S. Scrutton, *Green Chem.*, 2021, **23**, 4716–4732.
- 35 J. Coloma, T. Lugtenburg, M. Afendi, M. Lazzarotto, P. Bracco, P.-L. Hagedoorn, L. Gardossi and U. Hanefeld, *Catalysts*, 2020, **10**, 899–913.
- 36 W. Bohmer, A. Volkov, K. Engelmark Cassimjee and F. G. Mutti, *Adv. Synth. Catal.*, 2020, **362**, 1858–1867.
- 37 K. E. Cassimjee, P. Hendil-Forsell, A. Volkov, A. Krog, J. Malmo, T. E. V. Aune, W. Knecht, I. R. Miskelly, T. S. Moody and M. S. Humble, *ACS Omega*, 2017, **2**, 8674–8677.
- 38 M. Gand, C. Thoele, H. Mueller, H. Brundiek, G. Bashiri and M. Hoehne, *J. Biotechnol.*, 2016, **230**, 11–18.
- 39 W. Bhmer, L. Koenekoop, T. Simon and F. G. Mutti, *Molecules*, 2020, **25**, 2140–2156.
- 40 C. A. Godoy, B. de las Rivas and J. M. Guisan, *Process Biochem.*, 2014, **49**, 1324–1331.
- 41 R. C. Rodrigues, Á. Berenguer-Murcia, D. Carballares, R. Morellon-Sterling and R. Fernandez-Lafuente, *Biotechnol. Adv.*, 2021, **52**, 107821.
- 42 C. Ladavière, T. Delair, A. Domard, A. Novelli-Rousseau, B. Mandrand and F. Mallet, *Bioconjugate Chem.*, 1998, **9**, 655–661.
- 43 C. Ladavière, C. Lorenzo, A. Elaïssari, B. Mandrand and T. Delair, *Bioconjugate Chem.*, 2000, **11**, 146–152.
- 44 I. Serra, D. A. Cecchini, D. Ubiali, E. M. Manazza, A. M. Albertini and M. Terreni, *Eur. J. Org. Chem.*, 2009, 1384–1389.
- 45 S. Tural, B. Tural and A. S. Demir, *Chirality*, 2015, **27**, 635–642.
- 46 B. C. C. Pessela, C. Mateo, A. V. Carrascosa, A. Vian, J. L. Garcia, G. Rivas, C. Alfonso, J. M. Guisan and R. Fernandez-Lafuente, *Biomacromolecules*, 2003, **4**, 107–113.
- 47 C. Mateo, G. Fernandez-Lorente, E. Cortes, J. L. Garcia, R. Fernandez-Lafuente and J. M. Guisan, *Biotechnol. Bioeng.*, 2001, **76**, 269–276.
- 48 A. A. Ruediger, W. Bremser and O. I. Strube, *J. Coat. Technol. Res.*, 2016, **13**, 597–611.
- 49 V. Grazú, F. López-Gallego, T. Montes, O. Abian, R. González, J. A. Hermoso, J. L. García, C. Mateo and J. M. Guisán, *Process Biochem.*, 2010, **45**, 390–398.
- 50 V. Grazu, F. López-Gallego and J. M. Guisán, *Process Biochem.*, 2012, **47**, 2538–2541.
- 51 L. Cao, L. v Langen and R. A. Sheldon, *Curr. Opin. Biotechnol.*, 2003, **14**, 387–394.
- 52 L. Wang, A. Brock, B. Herberich and P. G. Schultz, *Science*, 2001, **292**, 498–500.
- 53 F. J. Isaacs, P. A. Carr, H. H. Wang, M. J. Lajoie, B. Sterling, L. Kraal, A. C. Tolonen, T. A. Gianoulis, D. B. Goodman, N. B. Reppas, C. J. Emig, D. Bang, S. J. Hwang, M. C. Jewett, J. M. Jacobson and G. M. Church, *Science*, 2011, **333**, 348–353.
- 54 M. J. Lajoie, A. J. Rovner, D. B. Goodman, H.-R. Aerni, A. D. Haimovich, G. Kuznetsov, J. A. Mercer, H. H. Wang, P. A. Carr and J. A. Mosberg, *Science*, 2013, **342**, 357–360.
- 55 M. Amiram, A. D. Haimovich, C. Fan, Y.-S. Wang, H.-R. Aerni, I. Ntai, D. W. Moonan, N. J. Ma, A. J. Rovner, S. H. Hong, N. L. Kelleher, A. L. Goodman, M. C. Jewett, D. Soell, J. Rinehart and F. J. Isaacs, *Nat. Biotechnol.*, 2015, **33**, 1272–1279.



- 56 J. A. Prescher and C. R. Bertozzi, *Nat. Chem. Biol.*, 2005, **1**, 13–21.
- 57 Y. Wang, W. Song, W. J. Hu and Q. Lin, *Angew. Chem., Int. Ed.*, 2009, **48**, 5330–5333.
- 58 E. M. Sletten and C. R. Bertozzi, *Angew. Chem., Int. Ed.*, 2009, **48**, 6974–6998.
- 59 K. K. Palaniappan and C. R. Bertozzi, *Chem. Rev.*, 2016, **116**, 14277–14306.
- 60 D. M. Patterson and J. A. Prescher, *Curr. Opin. Chem. Biol.*, 2015, **28**, 141–149.
- 61 M. King and A. Wagner, *Bioconjugate Chem.*, 2014, **25**, 825–839.
- 62 M. F. Debets, J. C. M. van Hest and F. Rutjes, *Org. Biomol. Chem.*, 2013, **11**, 6439–6455.
- 63 H. Zhan, S. Jiang, A. M. Jonker, I. A. B. Pijpers and D. W. P. M. Löwik, *J. Mater. Chem. B*, 2020, **8**, 5912–5920.
- 64 N. Contessi Negrini, A. Angelova Volponi, P. T. Sharpe and A. D. Celiz, *ACS Biomater. Sci. Eng.*, 2021, **7**, 4330–4346.
- 65 A. Battigelli, B. Almeida and A. Shukla, *Bioconjugate Chem.*, 2022, **33**, 263–271.
- 66 B. Zakeri, J. O. Fierer, E. Celik, E. C. Chittock, U. Schwarz-Linek, V. T. Moy and M. Howarth, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, E690–E697.
- 67 S. C. Reddington and M. Howarth, *Curr. Opin. Chem. Biol.*, 2015, **29**, 94–99.
- 68 Y. Wang, Y. Chang, R. Jia, H. Sun, J. Tian, H. Luo, H. Yu and Z. Shen, *Process Biochem.*, 2020, **95**, 260–268.
- 69 W.-B. Zhang, F. Sun, D. A. Tirrell and F. H. Arnold, *J. Am. Chem. Soc.*, 2013, **135**, 13988–13997.
- 70 A. I. Freitas, L. Domingues and T. Q. Aguiar, *J. Adv. Res.*, 2022, **36**, 249–264.
- 71 M. Li, F. Cheng, H. Li, W. Jin, C. Chen, W. He, G. Cheng and Q. Wang, *Langmuir*, 2019, **35**, 16466–16475.
- 72 H. Zheng, J. Chen, L. Su, Y. Zhao, Y. Yang, H. Zeng, G. Xu, S. Yang and W. Jiang, *Enzyme Microb. Technol.*, 2007, **41**, 474–479.
- 73 L. Zhang, N. Vila, T. Klein, G.-W. Kohring, I. Mazurenko, A. Walcarius and M. Etienne, *ACS Appl. Mater. Interfaces*, 2016, **8**, 17591–17598.
- 74 D. Weinrich, P.-C. Lin, P. Jonkheijm, U. T. T. Nguyen, H. Schroeder, C. M. Niemeyer, K. Alexandrov, R. Goody and H. Waldmann, *Angew. Chem., Int. Ed.*, 2010, **49**, 1252–1257.
- 75 X. Zhao, Y. Jin, X. Yuan, Z. Hou, Z. Chen, X. Fu, Q. Li, J. Wang and Y. Zhang, *Anal. Chem.*, 2020, **92**, 13750–13758.
- 76 J. Xiong, J. He, W. P. Xie, E. Hinojosa, C. S. R. Ambati, N. Putluri, H.-E. Kim, M. X. Zhu and G. Du, *J. Cell Sci.*, 2019, **132**, jcs235390.
- 77 G. O. Reznik, S. Vajda, C. R. Cantor and T. Sano, *Bioconjugate Chem.*, 2001, **12**, 1000–1004.
- 78 T. Ichihara, J. K. Akada, S. Kamei, S. Ohshiro, D. Sato, M. Fujimoto, Y. Kuramitsu and K. Nakamura, *J. Proteome Res.*, 2006, **5**, 2144–2151.
- 79 P. Wang, C. J. Zhang, G. C. Chen, Z. K. Na, S. Q. Yao and H. Y. Sun, *Chem. Commun.*, 2013, **49**, 8644–8646.
- 80 H. C. Wang, C. C. Yu, C. F. Liang, L. D. Huang, J. R. Hwu and C. C. Lin, *ChemBioChem*, 2014, **15**, 829–835.
- 81 A. I. Benítez-Mateos and F. Paradisi, *ChemSusChem*, 2022, **15**, e202102030.
- 82 M. Kindermann, N. George, N. Johnsson and K. Johnsson, *J. Am. Chem. Soc.*, 2003, **125**, 7810–7811.
- 83 R. Meyer and C. M. Niemeyer, *Small*, 2011, **7**, 3211–3218.
- 84 B. Sacca, R. Meyer, M. Erkelenz, K. Kiko, A. Arndt, H. Schroeder, K. S. Rabe and C. M. Niemeyer, *Angew. Chem., Int. Ed.*, 2010, **49**, 9378–9383.
- 85 A. Keppler, S. Gendreizig, T. Gronemeyer, H. Pick, H. Vogel and K. Johnsson, *Nat. Biotechnol.*, 2003, **21**, 86–89.
- 86 J. Wang, Y. Wang, J. Liu, Q. Li, G. Yin, Y. Zhang, C. Xiao, T. Fan, X. Zhao and X. Zheng, *Anal. Chem.*, 2019, **91**, 7385–7393.
- 87 M. Macias-Contreras, H. He, K. N. Little, J. P. Lee, R. P. Campbell, M. Royzen and L. Zhu, *Bioconjugate Chem.*, 2020, **31**, 1370–1381.
- 88 L. P. Encell, R. Friedman Ohana, K. Zimmerman, P. Otto, G. Vidugiris, M. G. Wood, G. V. Los, M. G. McDougall, C. Zimprich, N. Karassina, R. D. Learish, R. Hurst, J. Hartnett, S. Wheeler, P. Stecha, J. English, K. Zhao, J. Mendez, H. A. Benink, N. Murphy, D. L. Daniels, M. R. Slater, M. Urh, A. Darzins, D. H. Klaubert, R. F. Bulleit and K. V. Wood, *Curr. Chem. Genomics*, 2012, **6**, 55–71.
- 89 J. Döbber and M. Pohl, *J. Biotechnol.*, 2017, **241**, 170–174.
- 90 X. Fu, L. Li, X. Wen, R. Xu, Y. Xue, H. Zuo, Q. Liang, G. Feng, J. Wang and X. Zhao, *J. Chromatogr. A*, 2021, **1640**, 461946.
- 91 S. A. Slavoff, I. Chen, Y.-A. Choi and A. Y. Ting, *J. Am. Chem. Soc.*, 2008, **130**, 1160–1162.
- 92 I. Chen, M. Howarth, W. Lin and A. Y. Ting, *Nat. Methods*, 2005, **2**, 99–104.
- 93 M. Howarth, K. Takao, Y. Hayashi and A. Y. Ting, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 7583–7588.
- 94 E. de Boer, P. Rodriguez, E. Bonte, J. Krijgsveld, E. Katsantoni, A. Heck, F. Grosveld and J. Strouboulis, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 7480–7485.
- 95 J. Tykvar, P. Sacha, C. Barinka, T. Knedlik, J. Starkova, J. Lubkowski and J. Konvalinka, *Protein Expr. Purif.*, 2012, **82**, 106–115.
- 96 S. L. Khatwani, J. S. Kang, D. G. Mullen, M. A. Hast, L. S. Beese, M. D. Distefano and T. A. Taton, *Bioorg. Med. Chem.*, 2012, **20**, 4532–4539.
- 97 H. Miyao, Y. Ikeda, A. Shiraishi, Y. Kawakami and S. Sueda, *Anal. Biochem.*, 2015, **484**, 113–121.
- 98 K. R. Davenport, C. A. Smiths, H. Hofstetter, J. R. Horn and O. Hofstetter, *J. Chromatogr. B*, 2016, **1021**, 114–121.
- 99 Y. Maeda, T. Yoshino, M. Takahashi, H. Ginya, J. Asahina, H. Tajima and T. Matsunaga, *Appl. Environ. Microbiol.*, 2008, **74**, 5139–5145.
- 100 Y. Maeda, T. Yoshino and T. Matsunaga, *Appl. Environ. Microbiol.*, 2010, **76**, 5785–5790.
- 101 J. Alftren, K. E. Ottow and T. J. Hobley, *J. Mol. Catal. B-Enzym.*, 2013, **94**, 29–35.
- 102 T. Matsumoto, Y. Isogawa, T. Tanaka and A. Kondo, *Bio-sens. Bioelectron.*, 2018, **99**, 56–61.



- 103 S. Garg, G. S. Singaraju, S. Yengkhom and S. Rakshit, *Bioconjugate Chem.*, 2018, **29**, 1714–1719.
- 104 J. Fauser, S. Savitskiy, M. Fottner, V. Trauschke and B. Gulen, *Bioconjugate Chem.*, 2020, **31**, 1883–1892.
- 105 S. M. Qafari, G. Ahmadian and M. Mohammadi, *RSC Adv.*, 2017, **7**, 56006–56015.
- 106 M. Raeeszadeh-Sarmazdeh, R. Parthasarathy and E. T. Boder, *Colloids Surf., B*, 2015, **128**, 457–463.
- 107 K. P. Li, R. Z. Zhang, Y. Xu, Z. M. Wu, J. Li, X. T. Zhou, J. W. Jiang, H. Y. Liu and R. Xiao, *Sci. Rep.*, 2017, **7**, 3081.
- 108 L. Chan, H. F. Cross, J. K. She, G. Cavalli, H. F. Martins and C. Neylon, *PLoS One*, 2007, **2**, e1164.
- 109 F. Clow, J. D. Fraser and T. Proft, *Biotechnol. Lett.*, 2008, **30**, 1603–1607.
- 110 J. E. Glasgow, M. L. Salit and J. R. Cochran, *J. Am. Chem. Soc.*, 2016, **138**, 7496–7499.
- 111 R. K. Le, M. Raeeszadeh-Sarmazdeh, E. T. Boder and P. D. Frymier, *Langmuir*, 2015, **31**, 1180–1188.
- 112 M. Best, A. Degen, M. Baalman, T. T. Schmidt and R. Wombacher, *ChemBioChem*, 2015, **16**, 1158–1162.
- 113 J. G. Plaks, R. Falatach, M. Kastantin, J. A. Berberich and J. L. Kaar, *Bioconjugate Chem.*, 2015, **26**, 1104–1112.
- 114 M. Fernandez-Suarez, H. Baruah, L. Martinez-Hernandez, K. T. Xie, J. M. Baskin, C. R. Bertozzi and A. Y. Ting, *Nat. Biotechnol.*, 2007, **25**, 1483–1487.
- 115 J. Z. Yao, C. Uttamapinant, A. Poloukhtine, J. M. Baskin, J. A. Codelli, E. M. Sletten, C. R. Bertozzi, V. V. Popik and A. Y. Ting, *J. Am. Chem. Soc.*, 2012, **134**, 3720–3728.
- 116 M. Proeschel, M. E. Kraner, A. H. C. Horn, L. Schaefer, U. Sonnewald and H. Sticht, *PLoS One*, 2017, **12**, e0179740.
- 117 C. M. Buldun, J. X. Jean, M. R. Bedford and M. Howarth, *J. Am. Chem. Soc.*, 2018, **140**, 3008–3018.
- 118 G. Veggiani, T. Nakamura, M. D. Brenner, R. V. Gayet, J. Yan, C. V. Robinson and M. Howarth, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 1202–1207.
- 119 S.-C. Wu, C. Wang, J. Chin and S.-L. Wong, *Sci. Rep.*, 2019, **9**, 3359.
- 120 Y. Chen, Y. Zhao, X. Zhou, N. Liu, D. Ming, L. Zhu and L. Jiang, *Int. J. Biol. Macromol.*, 2021, **168**, 13–21.
- 121 Q. Xu, D. Ming, C. Shi, D. Lu, S. Tang, L. Jiang and H. Huang, *Process Biochem.*, 2019, **80**, 64–71.
- 122 D. M. Williams, G. Kaufman, H. Izadi, A. E. Gahm, S. M. Prophet, K. T. Vanderlick, C. O. Osuji and L. Regan, *ACS Appl. Nano Mater.*, 2018, **1**, 2483–2488.
- 123 X. Yang, J. Wei, Y. Wang, C. Yang, S. Zhao, C. Li, Y. Dong, K. Bai, Y. Li, H. Teng, D. Wang, N. Lyu, J. Li, X. Chang, X. Ning, Q. Ouyang, Y. Zhang and L. Qian, *ACS Synth. Biol.*, 2018, **7**, 2331–2339.
- 124 W.-H. Wu, J. Wei and W.-B. Zhang, *ACS Macro Lett.*, 2018, **7**, 1388–1393.
- 125 J. Fang and W.-b Zhang, *Acta Polym. Sin.*, 2018, 429–444, DOI: [10.1177/j.issn1000-3304.2018.18034](https://doi.org/10.1177/j.issn1000-3304.2018.18034).
- 126 J. L. Qu, S. Cao, Q. X. Wei, H. W. Zhang, R. Wang, W. Kang, T. Ma, L. Zhang, T. G. Liu, S. W. N. Au, F. Sun and J. Xia, *ACS Nano*, 2019, **13**, 9895–9906.
- 127 Q. Wei, S. He, J. Qu and J. Xia, *Bioconjugate Chem.*, 2020, **31**, 2413–2420.
- 128 Y. Arfi, M. Shamshoum, I. Rogachev, Y. Peleg and E. A. Bayer, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 9109–9114.
- 129 F. Peng, Q.-S. Chen, M.-H. Zong and W.-Y. Lou, *Mol. Catal.*, 2021, **510**, 111673.
- 130 X. Zhong, Y. Ma, X. Zhang, J. Zhang, B. Wu, F. Hollmann and Y. Wang, *Mol. Catal.*, 2022, **521**, 112188.
- 131 C. Schoene, J. O. Fierer, S. P. Bennett and M. Howarth, *Angew. Chem., Int. Ed.*, 2014, **53**, 6101–6104.
- 132 X. Gao, J. Fang, B. Xue, L. Fu and H. Li, *Biomacromolecules*, 2016, **17**, 2812–2819.
- 133 M. Ikeda, T. Tanida, T. Yoshii, K. Kurotani, S. Onogi, K. Urayama and I. Hamachi, *Nat. Chem.*, 2014, **6**, 511–518.
- 134 A. Chatterjee, C. Mahato and D. Das, *Angew. Chem., Int. Ed.*, 2021, **60**, 202–207.
- 135 I. W. Hamley, *Biomacromolecules*, 2021, **22**, 1835–1855.
- 136 L. Cai, Y. Chu, X. Liu, Y. Qiu, Z. Ge and G. Zhang, *Microb. Cell. Fact.*, 2021, **20**, 37.
- 137 J. M. Antos, M. W.-L. Popp, R. Ernst, G.-L. Chew, E. Spooner and H. L. Ploegh, *J. Biol. Chem.*, 2009, **284**, 16028–16036.
- 138 A. H. Keeble, A. Banerjee, M. P. Ferla, S. C. Reddington, I. N. A. K. Anuar and M. Howarth, *Angew. Chem., Int. Ed.*, 2017, **56**, 16521–16525.
- 139 A. H. Keeble, V. K. Yadav, M. P. Ferla, C. C. Bauer, E. Chuntharpursat-Bon, J. Huang, R. S. Bon and M. Howarth, *Cell Chem. Biol.*, 2022, **29**(2), 339–350.e10.
- 140 A. H. Keeble and M. Howarth, in *Metabolons and Supramolecular Enzyme Assemblies*, ed. C. SchmidtDannert and M. B. Quin, 2019, vol. 617, pp. 443–461.
- 141 F. Manea, V. G. Garda, B. Rad and C. M. Ajo-Franklin, *Biotechnol. Bioeng.*, 2020, **117**, 912–923.
- 142 J. Tian, R. Jia, D. Wenge, H. Sun, Y. Wang, Y. Chang and H. Luo, *Biotechnol. Lett.*, 2021, **43**, 1075–1087.
- 143 W. Dong, H. Sun, Q. Chen, L. Hou, Y. Chang and H. Luo, *Int. J. Biol. Macromol.*, 2022, **199**, 358–371.
- 144 L. L. Tan, S. S. Hoon and F. T. Wong, *PLoS One*, 2016, **11**, e0165074.
- 145 J. X. Wong, M. Gonzalez-Miro, A. J. Sutherland-Smith and B. H. A. Rehm, *Front. Bioeng. Biotechnol.*, 2020, **8**, 44.
- 146 J. X. Wong and B. H. A. Rehm, *Biomacromolecules*, 2018, **19**, 4098–4112.
- 147 P. Bitterwolf, S. Gallus, T. Peschke, E. Mittmann, C. Oelschlaeger, N. Willenbacher, K. S. Rabe and C. M. Niemeyer, *Chem. Sci.*, 2019, **10**, 9752–9757.
- 148 A. H. Keeble, P. Turkki, S. Stokes, I. N. A. K. Anuar, R. Rahikainen, V. P. Hytönen and M. Howarth, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 26523–26533.
- 149 N. M. Rachel and J. N. Pelletier, *Chem. Commun.*, 2016, **52**, 2541–2544.
- 150 S. K. Oteng-Pabi, C. Pardin, M. Stoica and J. W. Keillor, *Chem. Commun.*, 2014, **50**, 6604–6606.
- 151 N. M. Rachel, J. L. Toulouse and J. N. Pelletier, *Bioconjugate Chem.*, 2017, **28**, 2518–2523.
- 152 N. M. Rachel, D. Quaglia, E. Levesque, A. B. Charette and J. N. Pelletier, *Protein Sci.*, 2017, **26**, 2268–2279.



- 153 R. Sato, K. Minamihata, R. Wakabayashi, M. Goto and N. Kamiya, *Anal. Biochem.*, 2020, **600**, 113700.
- 154 J. H. Wang, M. Z. Tang, X. T. Yu, C. M. Xu, H. M. Yang and J. B. Tang, *Colloids Surf., B*, 2019, **177**, 506–511.
- 155 A. M. Wang, F. C. Du, F. Wang, Y. Q. Shen, W. F. Gao and P. F. Zhang, *Biochem. Eng. J.*, 2013, **73**, 86–92.
- 156 H. Cho and J. Jaworski, *Colloids Surf., B*, 2014, **122**, 846–850.
- 157 N. Janson, T. Heinks, T. Beuel, S. Alam, M. Hohne, U. T. Bornscheuer, G. F. von Mollard and N. Sewald, *ChemCatChem*, 2022, **14**, e202101485.
- 158 D. Schumacher, J. Helma, F. A. Mann, G. Pichler, F. Natale, E. Krause, M. C. Cardoso, C. P. R. Hackenberger and H. Leonhardt, *Angew. Chem., Int. Ed.*, 2015, **54**, 13787–13791.
- 159 C. Erck, R. Frank and J. Wehland, *Neurochem. Res.*, 2000, **25**, 5–10.
- 160 C. A. Arce, J. A. Rodriguez, H. S. Barra and R. Caputo, *Eur. J. Biochem.*, 1975, **59**, 145–149.
- 161 H. M. Kalisz, C. Erck, U. Plessmann and J. Wehland, *Biochim. Biophys. Acta*, 2000, **1481**, 131–138.
- 162 O. Monasterio, E. Nova, A. Lopez-Brauet and R. Lagos, *FEBS Lett.*, 1995, **374**, 165–168.
- 163 M. Joniau, K. Coudijzer and M. De Cuyper, *Anal. Biochem.*, 1990, **184**, 325–329.
- 164 A. Stengl, M. Gerlach, M. A. Kasper, C. P. R. Hackenberger, H. Leonhardt, D. Schumacher and J. Helma, *Org. Biomol. Chem.*, 2019, **17**, 4964–4969.
- 165 A. C. Obermeyer, J. B. Jarman and M. B. Francis, *J. Am. Chem. Soc.*, 2014, **136**, 9572–9579.
- 166 R. Sangsuwan, A. C. Obermeyer, P. Tachachartvanich, K. K. Palaniappan and M. B. Francis, *Chem. Commun.*, 2016, **52**, 10036–10039.
- 167 J. M. Hooker, A. P. Esser-Kahn and M. B. Francis, *J. Am. Chem. Soc.*, 2006, **128**, 15558–15559.
- 168 C. R. Behrens, J. M. Hooker, A. C. Obermeyer, D. W. Romanini, E. M. Katz and M. B. Francis, *J. Am. Chem. Soc.*, 2011, **133**, 16398–16401.
- 169 A. C. Obermeyer, J. B. Jarman, C. Netirojjanakul, K. El Muslemany and M. B. Francis, *Angew. Chem., Int. Ed.*, 2014, **53**, 1057–1061.
- 170 A. M. Marmelstein, M. J. Lobba, C. S. Mogilevsky, J. C. Maza, D. D. Brauer and M. B. Francis, *J. Am. Chem. Soc.*, 2020, **142**, 5078–5086.
- 171 S. L. Capehart, A. M. ElSohly, A. C. Obermeyer and M. B. Francis, *Bioconjugate Chem.*, 2014, **25**, 1888–1892.
- 172 D. Alvarez Dorta, D. Deniaud, M. Mevel and S. G. Gouin, *Chemistry*, 2020, **26**, 14257–14269.
- 173 S. Sato and H. Nakamura, *Molecules*, 2019, **24**, 3980–3996.
- 174 S. Isaschar-Ovdat and A. Fishman, *Food Chem.*, 2017, **232**, 587–594.
- 175 R. Lantto, E. Puolanne, K. Kruus, J. Buchert and K. Autio, *J. Agric. Food Chem.*, 2007, **55**, 1248–1255.
- 176 M. Goldfeder, M. Kanteev, S. Isaschar-Ovdat, N. Adir and A. Fishman, *Nat. Commun.*, 2014, **5**, 4505.
- 177 M. J. Lobba, C. Fellmann, A. M. Marmelstein, J. C. Maza, E. N. Kissman, S. A. Robinson, B. T. Staahl, C. Urnes, R. J. Lew, C. S. Mogilevsky, J. A. Doudna and M. B. Francis, *ACS Central Sci.*, 2020, **6**, 1564–1571.
- 178 A. V. Ramsey, A. J. Bischoff and M. B. Francis, *J. Am. Chem. Soc.*, 2021, **143**, 7342–7350.
- 179 C. S. Mogilevsky, M. J. Lobba, D. D. Brauer, A. M. Marmelstein, J. C. Maza, J. M. Gleason, J. A. Doudna and M. B. Francis, *J. Am. Chem. Soc.*, 2021, **143**, 13538–13547.
- 180 J. C. Maza, D. L. V. Bader, L. F. Xiao, A. M. Marmelstein, D. D. Brauer, A. M. ElSohly, M. J. Smith, S. W. Krska, C. A. Parish and M. B. Francis, *J. Am. Chem. Soc.*, 2019, **141**, 3885–3892.
- 181 M. J. Long and L. Hedstrom, *ChemBioChem*, 2012, **13**, 1818–1825.
- 182 K. Minamihata, M. Goto and N. Kamiya, *Bioconjugate Chem.*, 2011, **22**, 74–81.
- 183 S. Sato, K. Nakamura and H. Nakamura, *ChemBioChem*, 2017, **18**, 475–478.
- 184 M. L. Mattinen, M. Hellman, P. Permi, K. Autio, N. Kalkkinen and J. Buchert, *J. Agric. Food Chem.*, 2006, **54**, 8883–8890.
- 185 M. L. Mattinen, K. Kruus, J. Buchert, J. H. Nielsen, H. J. Andersen and C. L. Steffensen, *FEBS J.*, 2005, **272**, 3640–3650.
- 186 D. Permana, K. Minamihata, M. Goto and N. Kamiya, *J. Biosci. Bioeng.*, 2018, **126**, 559–566.
- 187 J. W. Chin, *Nature*, 2017, **550**, 53–60.
- 188 D. B. F. Johnson, J. F. Xu, Z. X. Shen, J. K. Takimoto, M. D. Schultz, R. J. Schmitz, Z. Xiang, J. R. Ecker, S. P. Briggs and L. Wang, *Nat. Chem. Biol.*, 2011, **7**, 779–786.
- 189 A. Z. Wang and R. Kluger, *Biochemistry*, 2014, **53**, 6793–6799.
- 190 Y. Yin, R. Wang, J. Zhang, Z. Luo, Q. Xiao, T. Xie, X. Pei, P. Gao and A. Wang, *ACS Appl. Mater. Interfaces*, 2021, **13**, 41454–41463.
- 191 J. F. Chen, J. Wang, Y. G. Bai, K. Li, E. S. Garcia, A. L. Ferguson and S. C. Zimmerman, *J. Am. Chem. Soc.*, 2018, **140**, 13695–13702.
- 192 H. Li, R. Wang, A. Wang, J. Zhang, Y. Yin, X. Pei and P. Zhang, *ACS Sustainable Chem. Eng.*, 2020, **8**, 6466–6478.
- 193 A. Dumas, L. Lercher, C. D. Spicer and B. G. Davis, *Chem. Sci.*, 2015, **6**, 50–69.
- 194 H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, **40**, 2004–2021.
- 195 R. L. Weller and S. R. Rajski, *Org. Lett.*, 2005, **7**, 2141–2144.
- 196 Z. Lin, Y. Amako, F. Kabir, H. A. Flaxman, B. Budnik and C. M. Woo, *J. Am. Chem. Soc.*, 2022, **144**, 606–614.
- 197 K. Liao, Y. Gong, R. Y. Zhu, C. Wang, F. Zhou and J. Zhou, *Angew. Chem., Int. Ed.*, 2021, **60**, 8488–8493.
- 198 D. Astruc, L. Y. Liang, A. Rapakousiou and J. Ruiz, *Acc. Chem. Res.*, 2012, **45**, 630–640.
- 199 N. Hauptstein, P. Pouyan, J. Kehrein, M. Dirauf, M. D. Driessen, M. Raschig, K. Licha, M. Gottschaldt, U. S. Schubert, R. Haag, L. Meinel, C. Sotriffer and T. Luehmann, *Biomacromolecules*, 2021, **22**, 4521–4534.



- 200 T. Vranken, E. S. Redeker, A. Miszta, B. Billen, W. Hermens, B. de Laat, P. Adriaensens, W. Guedens and T. J. Cleij, *Sens. Actuators, B*, 2017, **238**, 992–1000.
- 201 J. F. Chen, K. Li, S. E. Bonson and S. C. Zimmerman, *J. Am. Chem. Soc.*, 2020, **142**, 13966–13973.
- 202 B. K. Raliski, C. A. Howard and D. D. Young, *Bioconjugate Chem.*, 2014, **25**, 1916–1920.
- 203 M.-H. Seo, J. Han, Z. Jin, D.-W. Lee, H.-S. Park and H.-S. Kim, *Anal. Chem.*, 2011, **83**, 2841–2845.
- 204 V. Hong, S. I. Presolski, C. Ma and M. G. Finn, *Angew. Chem., Int. Ed.*, 2009, **48**, 9879–9883.
- 205 C. Besanceney-Webler, H. Jiang, T. Zheng, L. Feng, D. Soriano del Amo, W. Wang, L. M. Klivansky, F. L. Marlow, Y. Liu and P. Wu, *Angew. Chem., Int. Ed.*, 2011, **50**, 8051–8056.
- 206 N. J. Agard, J. A. Prescher and C. R. Bertozzi, *J. Am. Chem. Soc.*, 2004, **126**, 15046–15047.
- 207 A. M. Wang, F. C. Du, X. L. Pei, C. Y. Chen, S. G. Wu and Y. G. Zheng, *J. Mol. Catal. B-Enzym.*, 2016, **132**, 54–60.
- 208 A. I. Benitez-Mateos, I. Llarena, A. Sanchez-Iglesias and F. Lopez-Gallego, *ACS Synth. Biol.*, 2018, **7**, 875–884.
- 209 J. Zhang, R. Wang, Z. Luo, D. Jia, H. Chen, Q. Xiao, P. Zhang, X. Pei and A. Wang, *Mater. Chem. Front.*, 2022, **6**, 182–193.
- 210 Z. M. Png, H. Zeng, Q. Ye and J. Xu, *Chem. – Asian J.*, 2017, **12**, 2142–2159.
- 211 B. L. Oliveira, Z. Guo and G. J. L. Bernardes, *Chem. Soc. Rev.*, 2017, **46**, 4895–4950.
- 212 M. L. Blackman, M. Royzen and J. M. Fox, *J. Am. Chem. Soc.*, 2008, **130**, 13518–13519.
- 213 K. Lang, L. Davis, J. Torres-Kolbus, C. J. Chou, A. Deiters and J. W. Chin, *Nat. Chem.*, 2012, **4**, 298–304.
- 214 C. H. Kim, J. Y. Axup and P. G. Schultz, *Curr. Opin. Chem. Biol.*, 2013, **17**, 412–419.
- 215 V. F. C. Ferreira, B. L. Oliveira, A. D'Onofrio, C. M. Farinha, L. Gano, A. Paulo, G. J. L. Bernardes and F. Mendes, *Bioconjugate Chem.*, 2021, **32**, 121–132.
- 216 R. M. Bednar, T. W. Golbek, K. M. Kean, W. J. Brown, S. Jana, J. E. Baio, P. A. Karplus and R. A. Mehl, *ACS Appl. Mater. Interfaces*, 2019, **11**, 36391–36398.
- 217 S. Axon and D. James, *Curr. Opin. Green Sustainable Chem.*, 2018, **13**, 140–145.
- 218 S. Y. Lee, H. U. Kim, T. U. Chae, J. S. Cho, J. W. Kim, J. H. Shin, D. I. Kim, Y. S. Ko, W. D. Jang and Y. S. Jang, *Nat. Catal.*, 2019, **2**, 18–33.
- 219 R. A. Sheldon, *Philos. Trans. R. Soc., A*, 2020, **378**, 20190274.
- 220 J. O. Fierer, G. Veggiani and M. Howarth, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, E1176–E1181.
- 221 X.-D. Da, X.-L. Wu, Y. Liu and W.-B. Zhang, *Curr. Protoc.*, 2021, **1**, e99–e99.
- 222 B. Zakeri and M. Howarth, *J. Am. Chem. Soc.*, 2010, **132**, 4526–4527.
- 223 L. Langen, M. Janssen, N. Oosthoek, S. Pereira, V. K. Veda, F. V. Rantwijk and R. A. Sheldon, *Biotechnol. Bioeng.*, 2010, **79**, 224–228.
- 224 C. Mateo, V. Grazu, J. M. Palomo, F. Lopez-Gallego, R. Fernandez-Lafuente and J. M. Guisan, *Nat. Protoc.*, 2007, **2**, 1022–1033.
- 225 J. Camunas-Soler, A. Alemany and F. Ritort, *Science*, 2017, **355**, 412–415.
- 226 D. Balchin, M. Hayer-Hartl and F. U. Hartl, *Science*, 2016, **353**(6294), aac4354.
- 227 Z. Yu and Q. Lin, *J. Am. Chem. Soc.*, 2014, **136**, 4153–4156.
- 228 A. C. Forster and G. M. Church, *Genome Res.*, 2007, **17**, 1–6.
- 229 H. W. H. van Roekel, B. J. H. M. Rosier, L. H. H. Meijer, P. A. J. Hilbers, A. J. Markvoort, W. T. S. Huck and T. F. A. de Greef, *Chem. Soc. Rev.*, 2015, **44**, 7465–7483.
- 230 U. Nations, Transforming our World: The 2030 Agenda for Sustainable Development: Sustainable Development Knowledge Platform, 2020, Available online: <https://sustainabledevelopment.un.org/post2015/transformingourworld>.
- 231 C. Smaniotto, C. Battistella, L. Brunelli, E. Ruscio, A. Agodi, F. Auxilia, V. Baccolini, U. Gelatti, A. Odone, R. Prato, S. Tardivo, G. Voglino, F. Valent, S. Brusaferrero, F. Balzarini, M. Barchitta, A. Carli, F. Castelli, C. Coppola, G. Iannelli, M. Milazzo, B. Rosina, C. Salerno, R. Siliquini and S. Sisi, *Int. J. Environ. Res. Public Health*, 2020, **17**, 8968.
- 232 J. Yu, C. Wang, A. Wang, N. Li, X. Chen, X. Pei, P. Zhang and S. G. Wu, *RSC Adv.*, 2018, **8**, 16088–16094.
- 233 P. Gonzalez, F. Batista-Viera and B. M. Brena, *Int. J. Biotechnol.*, 2004, **6**, 338–345.
- 234 C. Mateo, J. M. Palomo, G. Fernandez-Lorente, J. M. Guisan and R. Fernandez-Lafuente, *Enzyme Microb. Technol.*, 2007, **40**, 1451–1463.
- 235 T. Kumaraguru, T. Harini and S. Basetty, *Tetrahedron: Asymmetry*, 2017, **28**, 1612–1617.
- 236 F. Batista-Viera, K. Ovsejevi and C. Manta, in *Immobilization of Enzymes and Cells*, ed. J. M. Guisan, Humana Press, Totowa, NJ, 2006, pp. 185–204, DOI: [10.1007/978-1-59745-053-9_17](https://doi.org/10.1007/978-1-59745-053-9_17).
- 237 J.-B. Zhu, E. M. Watson, J. Tang and E. Y.-X. Chen, *Science*, 2018, **360**, 398–403.
- 238 Y. Liu, H. Zhou, J. Z. Guo, W. M. Ren and X. B. Lu, *Angew. Chem., Int. Ed.*, 2017, **56**, 4862–4866.
- 239 M. Hong and E. Y. X. Chen, *Angew. Chem., Int. Ed.*, 2016, **55**, 4188–4193.
- 240 M. Hong and E. Y.-X. Chen, *Nat. Chem.*, 2016, **8**, 42–49.
- 241 D. Roura Padrosa, V. Marchini and F. Paradisi, *Bioinformatics*, 2021, **37**, 2761–2762.
- 242 C. Meng, Y. Hu, Y. Zhang and F. Guo, *Front. Bioeng. Biotechnol.*, 2020, **8**, 245.
- 243 M. Chai, S. Moradi, E. Erfani, M. Asadnia, V. Chen and A. Razmjou, *Chem. Mater.*, 2021, **33**, 8666–8676.
- 244 J. P. Smith, M. Liu, M. L. Lauro, M. Balasubramanian, J. H. Forstater, S. T. Grosser, Z. E. X. Dance, T. A. Rhodes, X. Bu and K. S. Booksh, *Analyst*, 2020, **145**, 7571–7581.
- 245 N. M. Ralbovsky and J. P. Smith, *Anal. Chem.*, 2021, **93**, 11973–11981.
- 246 J. H. Schrittwieser, S. Velikogne, M. Hall and W. Kroutil, *Chem. Rev.*, 2018, **118**, 270–348.
- 247 S. S. Mahmood, F. Yusof, M. S. Jami, S. Khanahmadi and H. Shah, *Process Biochem.*, 2015, **50**, 2144–2157.
- 248 M. A. Huffman, A. Fryszkowska, O. Alvizo, M. Borrarske, K. R. Campos, K. A. Canada, P. N. Devine,



- D. Duan, J. H. Forstater, S. T. Grosser, H. M. Halsey, G. J. Hughes, J. Jo, L. A. Joyce, J. N. Kolev, J. Liang, K. M. Maloney, B. F. Mann, N. M. Marshall, M. McLaughlin, J. C. Moore, G. S. Murphy, C. C. Nawrat, J. Nazor, S. Novick, N. R. Patel, A. Rodriguez-Granillo, S. A. Robaire, E. C. Sherer, M. D. Truppo, A. M. Whittaker, D. Verma, L. Xiao, Y. Xu and H. Yang, *Science*, 2019, **366**, 1255–1259.
- 249 H. O. Spivey and J. Ovadi, *Methods*, 1999, **19**, 306–321.
- 250 E. W. Miles, S. Rhee and D. R. Davies, *J. Biol. Chem.*, 1999, **274**, 12193–12196.
- 251 C. You and Y. H. P. Zhang, *ACS Synth. Biol.*, 2013, **2**, 102–110.
- 252 T. Peschke, P. Bitterwolf, K. S. Rabe and C. M. Niemeyer, *Chem. Eng. Technol.*, 2019, **42**, 2009–2017.
- 253 S. Tsitkov and H. Hess, *ACS Catal.*, 2019, **9**, 2432–2439.
- 254 J. Range, C. Halupczok, J. Lohmann, N. Swainston, C. Kettner, F. T. Bergmann, A. Weidemann, U. Wittig, S. Schnell and J. Pleiss, *FEBS J.*, 2021, DOI: [10.1111/febs.16318](https://doi.org/10.1111/febs.16318).
- 255 C. Zeymer and D. Hilvert, in *Annual Review of Biochemistry*, ed. R. D. Kornberg, 2018, vol. 87, pp. 131–157.
- 256 K. S. Rabe, J. Mueller, M. Skoupi and C. M. Niemeyer, *Angew. Chem., Int. Ed.*, 2017, **56**, 13574–13589.
- 257 J. Britton, S. Majumdar and G. A. Weiss, *Chem. Soc. Rev.*, 2018, **47**, 5891–5918.
- 258 A. I. Benitez-Mateos, D. R. Padrosa and F. Paradisi, *Nat. Chem.*, 2022, **14**, 489–499.
- 259 C. J. Hartley, C. C. Williams, J. A. Scoble, Q. I. Churches, A. North, N. G. French, T. Nebl, G. Coia, A. C. Warden, G. Simpson, A. R. Frazer, C. N. Jensen, N. J. Turner and C. Scott, *Nat. Catal.*, 2019, **2**, 1006–1015.
- 260 M. L. Contente and F. Paradisi, *Nat. Catal.*, 2018, **1**, 452–459.
- 261 A. Al-Shameri, M. C. Petrich, K. J. Puring, U. P. Apfel, B. M. Nestl and L. Lauterbach, *Angew. Chem., Int. Ed.*, 2020, **59**, 10929–10933.

